<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="alpers" content-type="chapter" from-where="body" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">gene</book-id>
    <book-title-group>
      <book-title>GeneReviews<sup>&#x000ae;</sup></book-title>
    </book-title-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Adam</surname>
          <given-names>Margaret P</given-names>
        </name>
        <role>Editor-in-Chief</role>
      </contrib>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ardinger</surname>
          <given-names>Holly H</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Pagon</surname>
          <given-names>Roberta A</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Wallace</surname>
          <given-names>Stephanie E</given-names>
        </name>
      </contrib>
      <role>Senior Editors</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Bean</surname>
          <given-names>Lora JH</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Mefford</surname>
          <given-names>Heather C</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Stephens</surname>
          <given-names>Karen</given-names>
        </name>
      </contrib>
      <role>Molecular Genetics</role>
    </contrib-group>
    <contrib-group>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Amemiya</surname>
          <given-names>Anne</given-names>
        </name>
      </contrib>
      <contrib contrib-type="editor">
        <name name-style="western">
          <surname>Ledbetter</surname>
          <given-names>Nikki</given-names>
        </name>
      </contrib>
      <role>Genetic Counseling</role>
    </contrib-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>1993</year>
    </pub-date>
    <pub-date publication-format="electronic" date-type="pubr">
      <year>2017</year>
    </pub-date>
    <issn>2372-0697</issn>
    <publisher>
      <publisher-name>University of Washington, Seattle</publisher-name>
      <publisher-loc>Seattle (WA)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 1993-2017, University of Washington, Seattle. GeneReviews is a registered trademark of the University of Washington, Seattle. All rights reserved.</copyright-statement>
      <copyright-year>2017</copyright-year>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://www.ncbi.nlm.nih.gov/books/NBK138602/">
        <license-p>GeneReviews&#x000ae; chapters are owned by the University of Washington. Permission is hereby granted to reproduce, distribute, and translate copies of content materials for noncommercial research purposes only, provided that (i) credit for source (<ext-link ext-link-type="uri" xlink:href="http://www.genereviews.org/">http://www.genereviews.org/</ext-link>) and copyright (&#x000a9; 1993-2017 University of Washington) are included with each copy; (ii) a link to the original material is provided whenever the material is published elsewhere on the Web; and (iii) reproducers, distributors, and/or translators comply with the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>. No further modifications are allowed. For clarity, excerpts of GeneReviews chapters for use in lab reports and clinic notes are a permitted use.</license-p>
        <license-p>For more information, see the <related-object source-id="gene" document-id="GRcopyright_permiss">GeneReviews&#x000ae; Copyright Notice and Usage Disclaimer</related-object>.</license-p>
        <license-p>For questions regarding permissions or whether a specified use is allowed, contact: <email>admasst@uw.edu</email>.</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Genetics</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Medicine</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-subject</meta-name>
        <meta-value>Diseases</meta-value>
      </custom-meta>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="ednotes">
      <p content-type="genetic_counseling">
<italic toggle="yes">Genetic counseling is the process of
providing individuals and families with information on the nature, inheritance,
and implications of genetic disorders to help them make informed medical and
personal decisions. The following section deals with genetic risk assessment and
the use of family history and genetic testing to clarify genetic status for
family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with
a genetics professional</italic>. &#x02014;ED.</p>
      <p content-type="resources">
<italic toggle="yes">GeneReviews staff has selected the following disease-specific and/or
umbrella support organizations and/or registries for the benefit of individuals
with this disorder and their families. GeneReviews is not responsible for the
information provided by other organizations. For information on selection
criteria, click <related-object source-id="gene" document-id="app4">here</related-object>.</italic></p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <book-part-id book-part-id-type="pmcid">alpers</book-part-id>
      <title-group>
        <title><italic toggle="yes">POLG</italic>-Related Disorders</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Cohen</surname>
            <given-names>Bruce H</given-names>
          </name>
          <degrees>MD</degrees>
          <aff>NeuroDevelopmental Science Center<break/>Children&#x02019;s Hospital Medical Center of Akron<break/>Northeast Ohio Medical University<break/>Akron, Ohio</aff>
          <email>bcohen@chmca.org</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Chinnery</surname>
            <given-names>Patrick F</given-names>
          </name>
          <degrees>BMedSci, MBBS, PhD, FRCPath, FRCP, FMedSci</degrees>
          <aff>Department of Clinical Neurosciences<break/>University of Cambridge<break/>Cambridge, United Kingdom</aff>
          <email>pfc@medschl.cam.ac.uk</email>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Copeland</surname>
            <given-names>William C</given-names>
          </name>
          <degrees>PhD</degrees>
          <aff>Mitochondrial DNA Replication Group<break/>Laboratory of Molecular Genetics<break/>National Institute of Environmental Health Sciences / NIH<break/>Research Triangle Park, North Carolina</aff>
          <email>copelan1@niehs.nih.gov</email>
        </contrib>
      </contrib-group>
      <pub-history>
        <date date-type="created">
          <day>16</day>
          <month>3</month>
          <year>2010</year>
        </date>
        <date date-type="updated">
          <day>18</day>
          <month>12</month>
          <year>2014</year>
        </date>
      </pub-history>
      <related-object link-type="parent-book-link" source-id="gene">GeneReviews<sup>&#x000ae;</sup></related-object>
      <related-object link-type="previous-part-link" source-id="gene" document-id="pnpla6-dis" document-type="chapter"><italic toggle="yes">PNPLA6-</italic>Related Disorders</related-object>
      <related-object link-type="next-part-link" source-id="gene" document-id="pol3-leuk" document-type="chapter">POLR3-Related Leukodystrophy</related-object>
      <abstract id="alpers.Summary">
        <title>Summary</title>
        <sec>
          <title>Clinical characteristics</title>
          <p><italic toggle="yes">POLG</italic>-related disorders comprise a continuum of overlapping phenotypes that were clinically defined long before their molecular basis was known. These phenotypes exemplify the diversity that can result from mutation of a given gene. Most affected individuals have some, but not all, of the features of a given phenotype; nonetheless, the following nomenclature can assist the clinician in diagnosis and management. Onset of the <italic toggle="yes">POLG</italic>-related disorders ranges from infancy to late adulthood.</p>
          <list list-type="bullet">
            <list-item>
              <p>Alpers-Huttenlocher syndrome (AHS), one of the most severe phenotypes, is characterized by childhood-onset progressive and ultimately severe encephalopathy with intractable epilepsy and hepatic failure.</p>
            </list-item>
            <list-item>
              <p>Childhood myocerebrohepatopathy spectrum (MCHS) presents between the first few months of life up to about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other findings can include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss.</p>
            </list-item>
            <list-item>
              <p>Myoclonic epilepsy myopathy sensory ataxia (MEMSA) now describes the spectrum of disorders with epilepsy, myopathy, and ataxia without ophthalmoplegia. MEMSA now includes the disorders previously described as spinocerebellar ataxia with epilepsy (SCAE).</p>
            </list-item>
            <list-item>
              <p>The ataxia neuropathy spectrum (ANS) includes the phenotypes previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO). About 90% of persons in the ANS have ataxia and neuropathy as core features. Approximately two thirds develop seizures and almost one half develop ophthalmoplegia; clinical myopathy is rare.</p>
            </list-item>
            <list-item>
              <p>Autosomal recessive progressive external ophthalmoplegia (arPEO) is characterized by progressive weakness of the extraocular eye muscles resulting in ptosis and ophthalmoparesis (or paresis of the extraocular muscles) without associated systemic involvement; however, caution is advised because many individuals with apparently isolated arPEO at the onset develop other manifestations of <italic toggle="yes">POLG</italic>-related disorders over years or decades. Of note, in the ANS spectrum the neuropathy commonly precedes the onset of PEO by years to decades.</p>
            </list-item>
            <list-item>
              <p>Autosomal dominant progressive external ophthalmoplegia (adPEO) typically includes a generalized myopathy and often variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, Parkinsonism, hypogonadism, and cataracts (in what has been called &#x0201c;chronic progressive external ophthalmoplegia plus,&#x0201d; or &#x0201c;CPEO+&#x0201d;).</p>
            </list-item>
          </list>
        </sec>
        <sec>
          <title>Diagnosis/testing</title>
          <p>Establishing the diagnosis of a <italic toggle="yes">POLG</italic>-related disorder relies on clinical findings and identification of two (biallelic) <italic toggle="yes">POLG</italic> pathogenic variants for all phenotypes except adPEO, for which identification of one <italic toggle="yes">POLG</italic> pathogenic variant is diagnostic.</p>
        </sec>
        <sec>
          <title>Management</title>
          <p><italic toggle="yes">Treatment of manifestations:</italic> Clinical management is largely supportive and involves conventional approaches for associated complications including physiotherapy, speech therapy, nutritional interventions, respiratory support, and management of seizures and movement disorders.</p>
          <p><italic toggle="yes">Prevention of secondary complications:</italic> Dose reductions of medications metabolized by hepatic enzymes to avoid toxicity.</p>
          <p><italic toggle="yes">Surveillance:</italic> Evaluations by a multidisciplinary team of healthcare providers based on clinical findings; monitoring of liver enzymes every two to four weeks after introduction of any new anticonvulsant.</p>
          <p><italic toggle="yes">Agents/circumstances to avoid:</italic> Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) because of the risk of precipitating and/or accelerating liver disease.</p>
        </sec>
        <sec>
          <title>Genetic counseling</title>
          <p>The <italic toggle="yes">POLG</italic>-related disorders in the spectrum of AHS, MCHS, MEMSA, ANS, and arPEO are inherited in an autosomal recessive manner. Autosomal dominant PEO (adPEO) is inherited in an autosomal dominant manner. For autosomal recessive phenotypes: heterozygotes (carriers) are generally believed to be asymptomatic; the offspring of carrier parents have a 25% chance of being affected, a 50% chance of being carriers, and a 25% chance of being unaffected and not carriers; carrier testing for at-risk family members is possible if the pathogenic variants in the family are known. For the autosomal dominant phenotype: most affected individuals have an affected parent; each child of an affected individual has a 50% chance of inheriting the pathogenic variant. For pregnancies at increased risk for all phenotypes, prenatal diagnosis is possible if the pathogenic variant(s) in the family are known.</p>
        </sec>
      </abstract>
    </book-part-meta>
    <body>
      <sec id="alpers.GeneReview_Scope">
        <title><italic toggle="yes">GeneReview</italic> Scope</title>
        <table-wrap id="alpers.Tc" orientation="portrait" position="anchor">
          <table frame="hsides" rules="groups">
            <thead>
              <tr>
                <th id="hd_h_alpers.Tc_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">POLG</italic>-Related Disorders: Included Phenotypes&#x000a0;<sup>1</sup></th>
              </tr>
            </thead>
            <tbody>
              <tr>
                <td headers="hd_h_alpers.Tc_1_1_1_1" valign="middle" align="left" rowspan="1" colspan="1"><list list-type="bullet"><list-item><p>Alpers-Huttenlocher syndrome</p></list-item><list-item><p>Childhood myocerebrohepatopathy spectrum disorders</p></list-item><list-item><p>Myoclonic epilepsy myopathy sensory ataxia</p></list-item><list-item><p>Ataxia neuropathy spectrum disorders</p></list-item><list-item><p>Autosomal recessive progressive external ophthalmoplegia</p></list-item><list-item><p>Autosomal dominant progressive external ophthalmoplegia</p></list-item></list>
</td>
              </tr>
            </tbody>
          </table>
          <table-wrap-foot>
            <fn>
              <p>For synonyms and outdated names see <xref ref-type="sec" rid="alpers.Nomenclature">Nomenclature</xref>.</p>
            </fn>
            <fn id="alpers.TF.c.1">
              <label>1. </label>
              <p>For other genetic causes of these phenotypes see <xref ref-type="sec" rid="alpers.Differential_Diagnosis">Differential Diagnosis</xref><italic toggle="yes">.</italic></p>
            </fn>
          </table-wrap-foot>
        </table-wrap>
      </sec>
      <sec id="alpers.Diagnosis">
        <title>Diagnosis</title>
        <sec id="alpers.Clinical_Diagnosis">
          <title>Clinical Diagnosis</title>
          <p><italic toggle="yes">POLG</italic>-related disorders comprise a continuum of overlapping phenotypes that were originally thought to be distinct clinical entities [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.lamantea.2002.211">Lamantea et al 2002</xref>, <xref ref-type="bibr" rid="alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.naviaux.2004.706">Naviaux &#x00026; Nguyen 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.ferrari.2005.723">Ferrari et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2005.1907">Luoma et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>].</p>
          <p>Description of the phenotypes associated with <italic toggle="yes">POLG</italic> pathogenic variants is ongoing; thus, it is likely that neither the full spectrum nor the extent to which the recognized phenotypes overlap is yet known.</p>
          <p>Clinical diagnostic criteria do not exist. Establishing the diagnosis of a <italic toggle="yes">POLG</italic>-related disorder requires identification of two (biallelic) <italic toggle="yes">POLG</italic> pathogenic variants for each of the following phenotypes except adPEO, for which identification of one dominant <italic toggle="yes">POLG</italic> pathogenic variant is diagnostic.</p>
          <p>
            <bold>Alpers-Huttenlocher syndrome (AHS)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Onset usually between ages two and four years and up to age 25-35</p>
            </list-item>
            <list-item>
              <p>Often preexisting developmental delays of variable severity</p>
            </list-item>
            <list-item>
              <p>Seizures</p>
            </list-item>
            <list-item>
              <p>Episodic psychomotor regression</p>
            </list-item>
            <list-item>
              <p>Liver dysfunction or failure, which may follow exposure to certain antiepileptic drugs</p>
            </list-item>
          </list>
          <p>
            <bold>Childhood myocerebrohepatopathy spectrum (MCHS)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Myopathy or hypotonia</p>
            </list-item>
            <list-item>
              <p>Developmental delay or encephalopathy</p>
            </list-item>
            <list-item>
              <p>Liver dysfunction</p>
            </list-item>
          </list>
          <p><bold>Myoclonic epilepsy myopathy sensory ataxia (MEMSA)</bold>; includes disorders previously referred to as spinocerebellar ataxia with epilepsy (SCAE)</p>
          <list list-type="bullet">
            <list-item>
              <p>Epilepsy</p>
            </list-item>
            <list-item>
              <p>Myoclonus</p>
            </list-item>
            <list-item>
              <p>Myopathy</p>
            </list-item>
            <list-item>
              <p>Sensory ataxia</p>
            </list-item>
          </list>
          <p><bold>Ataxia neuropathy spectrum (ANS)</bold>; includes disorders previously referred to as mitochondrial recessive ataxia syndrome (MIRAS) and sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO)</p>
          <list list-type="bullet">
            <list-item>
              <p>Cerebellar ataxia</p>
            </list-item>
            <list-item>
              <p>Sensory ataxia</p>
            </list-item>
            <list-item>
              <p>Axonal peripheral sensorimotor neuropathy</p>
            </list-item>
            <list-item>
              <p>Sensory neuropathy and dorsal root ganglionopathy</p>
            </list-item>
            <list-item>
              <p>Encephalopathy with seizures (in some cases)</p>
            </list-item>
            <list-item>
              <p>Ophthalmoplegia (in some cases)</p>
            </list-item>
            <list-item>
              <p>Dysarthria (in some cases)</p>
            </list-item>
          </list>
          <p>
            <bold>Autosomal recessive progressive external ophthalmoplegia (arPEO)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>PEO: ptosis and ophthalmoplegia</p>
            </list-item>
            <list-item>
              <p>Other features variably present: depression (mood disorder), premature ovarian failure, parkinsonism, ataxia, and a MNGIE-like phenotype, (see <related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter">Mitochondrial Neurogastrointestinal Encephalopathy Disease</related-object>)</p>
            </list-item>
          </list>
          <p>
            <bold>Autosomal dominant progressive external ophthalmoplegia (adPEO)</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>PEO: ptosis (drooping of the eyelids) and ophthalmoplegia (paralysis of the extraocular muscles)</p>
            </list-item>
            <list-item>
              <p>Other features variably present: limb weakness, parkinsonism, premature ovarian failure, and depression (mood disorder); often referred to as &#x0201c;chronic progressive external ophthalmoplegia plus&#x0201d; (CPEO+)</p>
            </list-item>
          </list>
        </sec>
        <sec id="alpers.Testing">
          <title>Testing</title>
          <p>Biochemical analysis of an affected tissue may reveal a respiratory chain defect and/or a defect of mitochondrial DNA (depletion or multiple deletions). However, biochemical findings on muscle biopsy can be completely normal in children [<xref ref-type="bibr" rid="alpers.REF.de_vries.2008.s299">de Vries et al 2008</xref>] and adults with a <italic toggle="yes">POLG</italic>-related disorder and in clinically unaffected tissue. Thus, these enzymatic defects are not sufficiently sensitive or specific in the diagnosis of <italic toggle="yes">POLG</italic>-related disorders and normal respiratory chain function or absence of mtDNA depletion should not be used to eliminate consideration of a <italic toggle="yes">POLG</italic>-related disorder.</p>
          <sec id="alpers.Molecular_Genetic_Testing">
            <title>Molecular Genetic Testing</title>
            <p><bold>Gene.</bold>
<italic toggle="yes">POLG</italic> is the only gene in which pathogenic variants are known to cause <italic toggle="yes">POLG-</italic>related disorders.</p>
            <p>
              <bold>Clinical testing</bold>
            </p>
            <table-wrap id="alpers.T.summary_of_molecular_genetic_te" orientation="portrait" position="anchor">
              <label>Table 1. </label>
              <caption>
                <p>Summary of Molecular Genetic Testing Used in <italic toggle="yes">POLG</italic>-Related Disorders</p>
              </caption>
              <table frame="hsides" rules="groups">
                <thead>
                  <tr>
                    <th id="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene&#x000a0;<sup>1</sup></th>
                    <th id="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Test Method</th>
                    <th id="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Proportion of Probands with a Pathogenic Variant Detectable by This Method</th>
                  </tr>
                </thead>
                <tbody>
                  <tr>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">
                      <italic toggle="yes">POLG</italic>
                    </td>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Targeted analysis for pathogenic variants&#x000a0;<sup>2,&#x000a0;3</sup></td>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">100% for the indicated pathogenic variants only&#x000a0;<sup>4</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis&#x000a0;<sup>5</sup>/ scanning for pathogenic variants&#x000a0;<sup>6</sup></td>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">&#x0003e;95%&#x000a0;<sup>7</sup></td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Sequence analysis of select exons&#x000a0;<sup>8</sup></td>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  </tr>
                  <tr>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Deletion/duplication analysis&#x000a0;<sup>9</sup></td>
                    <td headers="hd_h_alpers.T.summary_of_molecular_genetic_te_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Rare</td>
                  </tr>
                </tbody>
              </table>
              <table-wrap-foot>
                <fn id="alpers.TF.1.1">
                  <label>1. </label>
                  <p>See <related-object source-id="gene" document-id="alpers" object-id="alpers.molgen.TA">Table A. Genes and Databases</related-object> for chromosome locus and protein. See <xref ref-type="sec" rid="alpers.Molecular_Genetics">Molecular Genetics</xref> for information on allelic variants detected in this gene.</p>
                </fn>
                <fn id="alpers.TF.1.2">
                  <label>2. </label>
                  <p>Targeted analysis for pathogenic variants refers to testing for specific common <italic toggle="yes">POLG</italic> pathogenic variant(s).</p>
                </fn>
                <fn id="alpers.TF.1.3">
                  <label>3. </label>
                  <p>The <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Ala467Thr</xref> variant is the most common <italic toggle="yes">POLG</italic> pathogenic variant associated with AHS and is found in almost half of all affected individuals. Two other specific pathogenic variants tested are <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Trp748Ser</xref> and <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Gly848Ser</xref>. The p.Ala467Thr and p.Trp748Ser pathogenic variants are most often associated with AHS in European studies. The targeted pathogenic variants that are tested may vary by laboratory.</p>
                </fn>
                <fn id="alpers.TF.1.4">
                  <label>4. </label>
                  <p>Although collectively the p.Ala467Thr, p.Trp748Ser, and p.Gly848Ser pathogenic variants may be found in up to 70% of affected individuals, the need to detect two mutated alleles in an individual with this autosomal recessive disorder usually requires full sequence analysis.</p>
                </fn>
                <fn id="alpers.TF.1.5">
                  <label>5. </label>
                  <p>Sequence analysis detects variants that are benign, likely benign, of uncertain significance, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and missense, nonsense, and splice site variants; typically, exon or whole-gene deletions/duplications are not detected. For issues to consider in interpretation of sequence analysis results, click <related-object link-type="booklink" source-id="gene" document-id="app2" document-type="appendix">here</related-object>.</p>
                </fn>
                <fn id="alpers.TF.1.6">
                  <label>6. </label>
                  <p>Sequence analysis and scanning of the entire gene can have similar variant detection frequencies; however, variant detection rates for scanning may vary considerably between laboratories depending on the specific protocol used.</p>
                </fn>
                <fn id="alpers.TF.1.7">
                  <label>7. </label>
                  <p>Because of the difficulty of detecting microdeletions by conventional sequence analysis, variant frequency is less than 100%.</p>
                </fn>
                <fn id="alpers.TF.1.8">
                  <label>8. </label>
                  <p>Generally detects sequence variants in and flanking exon 7, 13, and 16, although the exons sequenced may vary by laboratory.</p>
                </fn>
                <fn id="alpers.TF.1.9">
                  <label>9. </label>
                  <p>Testing that identifies exon or whole-gene deletions/duplications not detectable by sequence analysis of the coding and flanking intronic regions of genomic DNA. Included in the variety of methods that may be used are: quantitative PCR, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and chromosomal microarray (CMA) that includes this gene/chromosome segment.</p>
                </fn>
              </table-wrap-foot>
            </table-wrap>
            <p>
              <bold>Interpretation of test results</bold>
            </p>
            <list list-type="bullet">
              <list-item>
                <p>Establishing the diagnosis of a <italic toggle="yes">POLG</italic>-related disorder requires identification of two (biallelic) <italic toggle="yes">POLG</italic> pathogenic variants for each of the phenotypes except adPEO, for which identification of one <italic toggle="yes">POLG</italic> pathogenic variant is diagnostic.</p>
              </list-item>
              <list-item>
                <p>In the 5% of simplex cases of PEO in which only a single pathogenic variant is identified, it can be difficult to distinguish between autosomal recessive inheritance and autosomal dominant inheritance caused by a <italic toggle="yes">de novo</italic> pathogenic variant. For example, the mother of a child with an MIRAS/ANS phenotype and compound heterozygosity for p.[Ala467Thr];[Trp748Ser] was herself heterozygous for the p.Trp748Ser pathogenic variant; she developed epilepsy at age 55 years and was found to have an axonal neuropathy, ataxia, mild PEO, and mild parkinsonism [<xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]. The significance of this finding is unknown.</p>
              </list-item>
            </list>
          </sec>
        </sec>
        <sec id="alpers.Testing_Strategy">
          <title>Testing Strategy</title>
          <p><bold>To confirm/establish the diagnosis in a proband.</bold> Standard clinical investigations can identify findings that, in the context of an appropriate family history, can suggest one of the <italic toggle="yes">POLG</italic>-related phenotypes.</p>
          <p>Confirmation of the diagnosis of a <italic toggle="yes">POLG</italic>-related disorder requires identification of <italic toggle="yes">POLG</italic> pathogenic variants by molecular genetic testing. Molecular testing approaches can include <bold>single-gene testing</bold>, use of a <bold>multi-gene panel</bold>, and <bold>more comprehensive</bold>
<bold>genomic testing</bold>.</p>
          <p><bold>Single-gene testing.</bold> One of the following two approaches can be used:</p>
          <list list-type="bullet">
            <list-item>
              <p>Direct sequencing of <italic toggle="yes">POLG</italic></p>
            </list-item>
            <list-item>
              <p>Two tiered analysis: targeted analysis for the common <italic toggle="yes">POLG</italic> pathogenic variants <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Ala467Thr</xref>, <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Trp748Ser</xref>, and <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Gly848Ser</xref>, followed by sequence analysis of the entire coding region if no pathogenic variants or only one pathogenic variant is found</p>
            </list-item>
          </list>
          <p>In persons meeting the diagnostic criteria of an autosomal recessive <italic toggle="yes">POLG</italic>-related disorder but in whom sequence analysis identifies only one disease-causing <italic toggle="yes">POLG</italic> allele, further testing may be considered to search for a second pathogenic variant in regulatory regions (e.g., the <italic toggle="yes">POLG</italic> promoter) or in related mitochondrial DNA replication genes such as <italic toggle="yes">TWNK</italic> (formerly <italic toggle="yes">C10orf2;</italic> (encodes the twinkle helicase) and <italic toggle="yes">POLG2</italic> to investigate the possibility of digenic inheritance (see <xref ref-type="sec" rid="alpers.Differential_Diagnosis">Differential Diagnosis</xref>).</p>
          <list list-type="bullet">
            <list-item>
              <p>Digenic inheritance has been reported in arPEO in a simplex case with pathogenic variants in <italic toggle="yes">POLG</italic> and <italic toggle="yes">TWNK</italic> [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2003a.175">Van Goethem et al 2003a</xref>].</p>
            </list-item>
            <list-item>
              <p>Oligonucleotide array should be strongly considered as microdeletions involving intragenic regions of <italic toggle="yes">POLG</italic> are reported and therefore relevant in a symptomatic individual with a single heterozygous pathogenic variant [<xref ref-type="bibr" rid="alpers.REF.compton.2011.104">Compton et al 2011</xref>, <xref ref-type="bibr" rid="alpers.REF.naess.2012.67">Naess et al 2012</xref>].</p>
            </list-item>
          </list>
          <p><bold>A</bold>
<bold>multi-gene panel</bold> that includes <italic toggle="yes">POLG</italic> and other genes of interest may also be considered (see <xref ref-type="sec" rid="alpers.Differential_Diagnosis">Differential Diagnosis</xref>). Note: The genes included and the methods used in multi-gene panels vary by laboratory and over time.</p>
          <p>For more information on multi-gene panels click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.MultiGene_Panels" object-type="sec">here</related-object>.</p>
          <p><bold>More comprehensive genomic testing</bold> (when available) may be considered if single-gene testing (and/or use of a multi-gene panel) fails to confirm a diagnosis in an individual with features of a <italic toggle="yes">POLG</italic>-related disorder. For more information on comprehensive genome sequencing click <related-object link-type="booklink" source-id="gene" document-id="app5" document-type="appendix" object-id="app5.Comprehensive_Genome_Sequencing" object-type="sec">here</related-object>.</p>
        </sec>
      </sec>
      <sec id="alpers.Clinical_Characteristics">
        <title>Clinical Characteristics</title>
        <sec id="alpers.Clinical_Description">
          <title>Clinical Description</title>
          <p><italic toggle="yes">POLG</italic>-related disorders comprise a continuum of broad and overlapping phenotypes that can be distinct clinical entities or consist of a spectrum of overlapping phenotypes [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.lamantea.2002.211">Lamantea et al 2002</xref>, <xref ref-type="bibr" rid="alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.naviaux.2004.706">Naviaux &#x00026; Nguyen 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.ferrari.2005.723">Ferrari et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2005.1907">Luoma et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>]. Presentations within a given family are usually similar. Although almost any organ system can be involved, evidence to date suggests that diabetes and cardiomyopathy are not common in <italic toggle="yes">POLG</italic>-related disorders, distinguishing them from other multisystem mitochondrial diseases.</p>
          <p><xref ref-type="table" rid="alpers.T.clinical_findings_in_polgrelate">Table 2</xref> summarizes the clinical findings in <italic toggle="yes">POLG</italic>-related disorders. Because the description of new <italic toggle="yes">POLG</italic> pathogenic variants is ongoing, knowledge of their associated phenotypes continues to evolve.</p>
          <table-wrap id="alpers.T.clinical_findings_in_polgrelate" orientation="portrait" position="anchor">
            <label>Table 2. </label>
            <caption>
              <p>Clinical Findings in <italic toggle="yes">POLG</italic>-Related Disorders</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Finding</th>
                  <th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Manifestation</th>
                  <th id="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Notes/References</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Psychiatric illness</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Depression</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al [2004]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Psychosis</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Dementia</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">Seizure disorder</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Myoclonus</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Common in children [<xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>] and adults with ataxia [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Focal motor seizures</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al [2006]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Generalized seizures</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.winterthun.2005.1204">Winterthun et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Status epilepticus</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al [2006]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Extrapyramidal movement disorder</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Parkinsonism</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Responds to levodopa [<xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.mancuso.2004.1777">Mancuso et al 2004</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Chorea</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Cerebellar involvement</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ataxia</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.winterthun.2005.1204">Winterthun et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">&#x0201c;Cerebrovascular&#x0201d; involvement</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Migraine</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">May precede other features by many years [<xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Stroke-like episodes</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Usually asymptomatic in children, diagnosed on imaging [<xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Special sensory</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sensorineural deafness</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</xref>, <xref ref-type="bibr" rid="alpers.REF.filosto.2003.1279">Filosto et al [2003]</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Retinopathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="3" valign="middle" align="left" scope="row" colspan="1">Myopathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Ptosis and external ophthalmoplegia</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">May be isolated ptosis [<xref ref-type="bibr" rid="alpers.REF.luoma.2005.1907">Luoma et al 2005</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Proximal myopathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Distal myopathy reported [<xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Exercise intolerance</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.di_fonzo.2003.498">Di Fonzo et al [2003]</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Peripheral neuropathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Sensory neuronopathy / ganglionopathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Corresponds to the acronym SANDO [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</xref>]; profound sensory ataxia</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Axonal sensorimotor neuropathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.davidzon.2006.859">Davidzon et al [2006]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">Endocrine/gonadal system</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Diabetes mellitus</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Primary ovarian failure</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Ovarian dysgenesis</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.bekheirnia.2012.209">Bekheirnia et al [2012]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Primary testicular failure</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.filosto.2003.1279">Filosto et al [2003]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">Gastrointestinal system</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Liver failure</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Spontaneous or precipitated by sodium valproate in children [<xref ref-type="bibr" rid="alpers.REF.naviaux.2004.706">Naviaux &#x00026; Nguyen 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.nguyen.2005.1493">Nguyen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>]; also in adults with ataxia [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">Gastrointestinal dysmotility</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.filosto.2003.1279">Filosto et al [2003]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Heart</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Cardiomyopathy</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"><xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al [2004]</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">Ocular</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Cataract</td>
                  <td headers="hd_h_alpers.T.clinical_findings_in_polgrelate_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.bekheirnia.2012.209">Bekheirnia et al [2012]</xref>
                  </td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Reproduced and modified from <xref ref-type="bibr" rid="alpers.REF.hudson.2006.r244">Hudson &#x00026; Chinnery [2006]</xref></p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>Although some affected individuals present with a classic syndrome, many have some, but not all, of the features of one or more of the recognized phenotypes. <italic toggle="yes">POLG</italic>-related disorders can therefore be considered as an overlapping spectrum of disease presenting from early childhood to late adulthood. The age of onset broadly correlates with the major clinical pattern seen in individual cases.</p>
          <sec id="alpers.AlpersHuttenlocher_Syndrome_AHS">
            <title>Alpers-Huttenlocher Syndrome (AHS)</title>
            <p>AHS, one of the most severe phenotypic manifestations in the spectrum of <italic toggle="yes">POLG</italic>-related disorders, is characterized by a progressive and ultimately severe encephalopathy with intractable epilepsy, neuropathy, and hepatic failure. Although AHS is usually fatal, the age of onset, the rate of neurologic degeneration, the presence of hepatic failure, and the age of death vary [<xref ref-type="bibr" rid="alpers.REF.naviaux.1999.54">Naviaux et al 1999</xref>, <xref ref-type="bibr" rid="alpers.REF.gauthiervillars.2001.150">Gauthier-Villars et al 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.davidzon.2005.921">Davidzon et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.naviaux.2005.491">Naviaux &#x00026; Nguyen 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.davidzon.2006.859">Davidzon et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.nguyen.2006.108">Nguyen et al 2006</xref>].</p>
            <p>Children with AHS appear healthy at birth and may develop normally over the first few weeks to years of life. Some have variable degrees of developmental delay prior to the onset of the recognition of neurodegeneration. Onset is usually between ages two and four years, but ranges from one month to 36 years.</p>
            <p>Preexisting and apparently static developmental delays of variable severity have been noted, although some children who later develop manifestations appear initially to be developmentally normal.</p>
            <p>Seizures are the first sign of AHS in about 50% of affected children. Seizures may be simple focal, primary generalized, or myoclonic. The most common early seizure types are partial seizures and secondary generalized tonic-clonic seizures. In some instances the first seizure type is epilepsia partialis continua (EPC), a classic seizure type in which the motor seizure involves only one portion of the body (e.g., a limb) with a constant and repetitive myoclonic jerking, continuing for hours or days with or without dramatic effects on consciousness. EPC is not always apparent as an abnormality on electroencephalogram (EEG) and can be mistaken for a conversion reaction. Other seizure types include apparent myoclonic seizures. In some children the first seizure presents with status epilepticus. Over time the seizures can evolve into a complex epileptic disorder such as focal status epilepticus, epilepsia partialis continua, or multifocal myoclonic epilepsy [<xref ref-type="bibr" rid="alpers.REF.naviaux.1999.54">Naviaux et al 1999</xref>, <xref ref-type="bibr" rid="alpers.REF.gauthiervillars.2001.150">Gauthier-Villars et al 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.naviaux.2005.491">Naviaux &#x00026; Nguyen 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.winterthun.2005.1204">Winterthun et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>].</p>
            <p>In some children the seizures initially are controlled with usual dosages of anticonvulsants; in others the seizures, such as EPC, are refractory from the onset. Over time the seizures become increasingly resistant to anticonvulsant therapy. See <xref ref-type="sec" rid="alpers.Treatment_of_Manifestations">Treatment of Manifestations</xref> for further information about management of seizures. Of note, valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) can precipitate the liver dysfunction in AHS and should be avoided [<xref ref-type="bibr" rid="alpers.REF.saneto.2010.140">Saneto et al 2010</xref>].</p>
            <p>Headaches, another common first presenting symptom, typically are associated with visual sensations or visual auras that reflect early occipital lobe dysfunction [<xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]. Stroke and stroke-like episodes may occur in this disorder as well [<xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>].</p>
            <p>Movement disorders, primarily myoclonus and choreoathetosis, are common [<xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>].</p>
            <p>Myoclonus can be difficult to distinguish from myoclonic seizures and EPC. Palatal myoclonus resulting from involvement of the inferior olivary nuclei can be seen as well. Some develop parkinsonism, which may temporarily respond to levodopa [<xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.mancuso.2004.1777">Mancuso et al 2004</xref>].</p>
            <p>Neuropathy and ataxia develop in all persons with AHS unless the disease process is so rapid that it results in early death. All neurologic signs and symptoms, including ataxia and nystagmus, may worsen during infections or with other physiologic stressors.</p>
            <p>Areflexia (resulting from neuropathy) and hypotonia (possibly the result of generalized weakness as part of systemic illness or pyramidal or extrapyramidal dysfunction) are often both present early in the disease course. They are later followed by complete loss of motor function due to spastic paraparesis resulting from progressive loss of cortical neuronal function.</p>
            <p>Episodic psychomotor regression is variably present at the time of initial consideration of the diagnosis. The major motor manifestation is a progressive spastic paraparesis that evolves over months to years. Progressive spasticity involving all motor functions occurs universally; onset occurs at variable stages of the illness.</p>
            <p>Loss of cognitive function occurs throughout the course of the disease, but the time of onset and rate of progression are variable. Significant sudden or rapid regression is often seen during infectious illnesses. The clinical manifestations may include somnolence, loss of concentration, loss of language skills (both receptive and expressive), irritability with loss of normal emotional responses, and memory deficits. In addition to the dementia caused by loss of brain tissue and the refractory seizures, the high dosages of medication used to treat those seizures can lead to significant cognitive impairment.</p>
            <p>Cortical visual loss leading to blindness may appear months to years after the onset of other neurologic manifestations. Retinopathy (<related-object link-type="booklink" source-id="gene" document-id="rp-overview" document-type="chapter">retinitis pigmentosa</related-object>) may also play a less important role in vision loss [<xref ref-type="bibr" rid="alpers.REF.di_fonzo.2003.498">Di Fonzo et al 2003</xref>, <xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>]. Hearing loss is variable [<xref ref-type="bibr" rid="alpers.REF.di_fonzo.2003.498">Di Fonzo et al 2003</xref>, <xref ref-type="bibr" rid="alpers.REF.filosto.2003.1279">Filosto et al 2003</xref>, <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al 2006</xref>].</p>
            <p>Liver involvement can progress rapidly to end-stage liver failure within a few months, although this is highly variable. End-stage liver disease is often heralded by hypoalbuminemia and prolonged coagulation time, followed shortly thereafter by fasting hypoglycemia and hyperammonemia. Rapid onset of liver failure is described when valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) have been used to treat seizures, although the introduction of other anticonvulsants, including phenytoin, may also play a role in onset of hepatic failure. Longer survival in AHS through improved care for those with profound dementia and motor dysfunction results in the occurrence of late-onset hepatic involvement in a higher percentage of children with AHS now than previously noted.</p>
            <p>Disease progression is variable in timing and rapidity. Loss of neurologic function culminates in dementia, spastic quadriparesis from corticospinal tract involvement, visual loss, and death. The rate of neurodegeneration varies and is marked by periods of stability. The degree of dementia is often difficult to assess because of the frequent seizures and high therapeutic doses of anticonvulsants, which can cloud the sensorium. The typical life expectancy from onset of first symptoms ranges from three months to 12 years.</p>
            <p>EEG findings include high-amplitude slow activity with smaller polyspikes or intermittent continuous spike-wave activity [<xref ref-type="bibr" rid="alpers.REF.w_rle.1998.63">W&#x000f6;rle et al 1998</xref>].</p>
            <p>Note: Although not specific, this EEG pattern in the setting of the clinical history may be helpful in the diagnosis. As in many cases of epilepsia partialis continua, the EEG may not show epileptic spikes over the involved hemisphere, but may be normal or show only focal slowing of the background rhythm. The diversity of EEG patterns in AHS is increasingly recognized [<xref ref-type="bibr" rid="alpers.REF.boyd.1986.75">Boyd et al 1986</xref>, <xref ref-type="bibr" rid="alpers.REF.saneto.2010.140">Saneto et al 2010</xref>].</p>
            <p>Cerebrospinal fluid (CSF) protein is generally elevated in individuals with AHS. Aside from <related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter">Kearns-Sayre syndrome</related-object>, the PEO+ presentations of <related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter">MELAS</related-object>, and possibly pathogenic variants in other genes involved in mtDNA maintenance, the CSF protein is usually normal in mitochondrial disorders [<xref ref-type="bibr" rid="alpers.REF.hirano.2001.2163">Hirano &#x00026; DiMauro 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.nguyen.2005.1493">Nguyen et al 2005</xref>].</p>
            <p><bold>Neuroimaging.</bold> Computerized tomography (CT) or magnetic resonance imaging (MRI) of the brain may be normal early in the course of AHS. As the illness evolves neuroimaging shows gliosis (initially more pronounced in the occipital lobe regions) and generalized brain atrophy.</p>
            <p>Note: In <related-object link-type="booklink" source-id="gene" document-id="narp" document-type="chapter">Leigh syndrome</related-object> MRI changes most often occur initially in the brain stem and the gliosis &#x02018;migrates&#x02019; over time to involve the deep gray masses and cortex, whereas in AHS the initial lesions form in the cerebral cortex (usually the occipital lobes), followed by the cerebellum, basal ganglia, thalamus, and brain stem.</p>
            <p>FLAIR and T<sub>2</sub> sequence images demonstrate high signal intensity in deep gray matter nuclei, especially in the thalamus and cerebellum [<xref ref-type="bibr" rid="alpers.REF.smith.1996.235">Smith et al 1996</xref>]. Lesions described in the inferior olivary nuclei may also be a part of AHS and are associated with palatal myoclonus.</p>
            <p><bold>Pathophysiology.</bold> Depletion of mitochondrial DNA (mtDNA) develops in clinically affected tissues causing a mitochondrial oxidative-phosphorylation defect resulting in the clinical findings of AHS.</p>
            <p><bold>Brain.</bold> The gross appearance of the brain varies from normal to severe atrophy, depending on the state of disease progression. The central nervous system regions affected in AHS are the same as those affected by Leigh syndrome but typically evolve in the reverse order. For example, in AHS the gliosis is most severe and occurs earliest in the cerebral cortex, followed by the cerebellum, basal ganglia, and brain stem. Involved regions demonstrate neuronal degeneration, characteristic spongiform or microcystic degeneration, and, as seen in Leigh syndrome, gliosis, necrosis, and capillary proliferation. The cortical ribbon shows patchy lesions, but the calcarine cortex, which is characteristically involved early in the course of the disease, is usually narrowed, granular, and discolored.</p>
            <p>Microscopic abnormalities, present throughout the cerebral cortex, evolve as the disease progresses. Early in the course of the disease spongiosis, astrocytosis, and neuronal loss are prevalent in the superficial cortex. Later the deeper laminae are affected. In the most advanced stage the entire cortex becomes a thin dense gliotic scar. Usually the striate cortex is the most affected part of the brain followed by the thalamus, hippocampus, and cerebellum. These pathologic features differ from those resulting from hypoxic injury, recurrent seizures, or other causes of hepatic failure.</p>
            <p><bold>Liver.</bold> Liver histology may demonstrate macro- and microvesicular steatosis, centrilobular necrosis, disorganization of the normal lobular architecture, hepatocyte loss with or without bridging fibrosis or cirrhosis, regenerative nodules, bile duct proliferation, or mitochondrial proliferation with a vivid eosinophilic cytoplasm (oncocytic change). Florid cirrhosis occurs late in the disease. This pathology differs from that seen in chemically induced or toxic hepatopathies.</p>
          </sec>
          <sec id="alpers.Childhood_Myocerebrohepatopathy_S">
            <title>Childhood Myocerebrohepatopathy Spectrum (MCHS)</title>
            <p>MCHS presents between the first few months of life up to about age three years with developmental delay or dementia, lactic acidosis, and a myopathy with failure to thrive. Other features of a mitochondrial disorder that may be present include liver failure, renal tubular acidosis, pancreatitis, cyclic vomiting, and hearing loss. Seizures are not present, at least early in the disease course [<xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>].</p>
          </sec>
          <sec id="alpers.Myoclonic_Epilepsy_Myopathy_Senso">
            <title>Myoclonic Epilepsy Myopathy Sensory Ataxia (MEMSA)</title>
            <p>Previously referred to as spinocerebellar ataxia with epilepsy (SCAE), MEMSA now describes the spectrum of disorders with myopathy, epilepsy, and ataxia without ophthalmoplegia. Cerebellar ataxia, generally the first sign, begins in young adulthood as a subclinical sensory polyneuropathy. Epilepsy develops in later years, often beginning focally in the right arm and then spreading to become generalized. The seizures may be refractory to conventional therapy, including anesthesia. Recurrent bouts of seizure activity are accompanied by progressive interictal encephalopathy. The myopathy in MEMSA may be distal or proximal, and, as in the other <italic toggle="yes">POLG</italic> spectrum disorders, it also may present as exercise intolerance.</p>
          </sec>
          <sec id="alpers.Ataxia_Neuropathy_Spectrum_ANS">
            <title>Ataxia Neuropathy Spectrum (ANS)</title>
            <p>ANS includes mitochondrial recessive ataxia syndrome (MIRAS) and a separate entity known as sensory ataxia neuropathy dysarthria and ophthalmoplegia (SANDO) [<xref ref-type="bibr" rid="alpers.REF.fadic.1997.239">Fadic et al 1997</xref>]. ANS is characterized by ataxia, neuropathy, and in most, but not all affected individuals, an encephalopathy with seizures. The encephalopathy is similar to that seen in AHS but tends to be more slowly progressive and can even be mild. The neuropathy may be sensory, motor, or mixed and can be severe enough to contribute to ataxia &#x02014; so-called sensory ataxia. About 25% of affected individuals have cramps, but clinical myopathy is rare.</p>
            <p>Other features may include myoclonus, blindness, and liver dysfunction [<xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>]. Liver findings range from no dysfunction to elevated enzymes and mild synthetic dysfunction to florid liver failure on occasion [<xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>, <xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>]. Psychiatric illness including depression is common. Headache, generally migrainous, is also common and may precede other symptoms by many years.</p>
            <p>Although muscle pathology may show COX-negative fibers, there may be no pathologic findings.</p>
          </sec>
          <sec id="alpers.Autosomal_Recessive_Progressive_E">
            <title>Autosomal Recessive Progressive External Ophthalmoplegia (arPEO)</title>
            <p>Progressive PEO without systemic involvement is the hallmark of arPEO. Caution needs to be exercised, however, when making the diagnosis of arPEO, as some <italic toggle="yes">POLG</italic> pathogenic variants associated with arPEO are also associated with ANS and other <italic toggle="yes">POLG</italic>-related disorders with systemic involvement. Thus, many individuals who have no other clinical findings at the time of diagnosis with isolated arPEO develop other manifestations of <italic toggle="yes">POLG</italic>-related disorders over subsequent years or decades [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.lamantea.2002.211">Lamantea et al 2002</xref>, <xref ref-type="bibr" rid="alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</xref>]. In the past these findings were designated &#x0201c;PEO+&#x0201d; or &#x0201c;PEO+&#x0201d; disease.</p>
          </sec>
          <sec id="alpers.Autosomal_Dominant_Progressive_Ex">
            <title>Autosomal Dominant Progressive External Ophthalmoplegia (adPEO)</title>
            <p>The universal manifestation of this adult-onset disorder is progressive weakness of the extraocular eye muscles resulting in ptosis and strabismus [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>]. A generalized myopathy is present in most affected individuals, leading to early fatigue and exercise intolerance. Some affected individuals (in what has been called &#x0201c;chronic progressive external ophthalmoplegia plus, or CPEO+) have variable degrees of sensorineural hearing loss, axonal neuropathy, ataxia, depression, parkinsonism, hypogonadism, and cataracts [<xref ref-type="bibr" rid="alpers.REF.luoma.2004.875">Luoma et al 2004</xref>, <xref ref-type="bibr" rid="alpers.REF.pagnamenta.2006.2467">Pagnamenta et al 2006</xref>]. Cardiomyopathy and gastrointestinal dysmotility are less common.</p>
          </sec>
        </sec>
        <sec id="alpers.GenotypePhenotype_Correlations">
          <title>Genotype-Phenotype Correlations</title>
          <p>Genotype-phenotype correlations are not possible because all combinations of pathogenic variant type and location have been associated with the entire phenotypic spectrum and both autosomal recessive and autosomal dominant inheritance.</p>
        </sec>
        <sec id="alpers.Nomenclature">
          <title>Nomenclature</title>
          <p>Alpers-Huttenlocher syndrome (AHS) is named after Bernard Alpers, who first described the disease in 1931, and Peter Huttenlocher, who with his colleagues described the associated liver disease and autosomal recessive mode of inheritance [<xref ref-type="bibr" rid="alpers.REF.huttenlocher.1976.186">Huttenlocher et al 1976</xref>].</p>
          <p>In the older literature, autosomal dominant progressive external ophthalmoplegia (adPEO) associated with additional findings was labeled &#x0201c;chronic progressive external ophthalmoplegia plus&#x0201d; (CPEO+).</p>
        </sec>
        <sec id="alpers.Prevalence">
          <title>Prevalence</title>
          <p>AHS is reported to affect approximately one in 51,000 people [<xref ref-type="bibr" rid="alpers.REF.darin.2001.377">Darin et al 2001</xref>]; however, because some pathogenic variants are found at high frequencies in certain populations, the frequency may vary greatly within any population.</p>
          <p>The frequency of the most common autosomal recessive pathogenic variants (<xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Ala467Thr</xref>: ~0.2%-0.6%; <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.[Trp748Ser;Glu1143Gly]</xref> (indicating two variants in <italic toggle="yes">cis</italic> configuration on the same allele): ~0.1%-0.8%; <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Gly848Ser</xref>: ~0.05%-0.1%; and <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">p.Pro587Leu</xref>: ~0.05%) suggests that the sum frequency of the 20 most common pathogenic variants may be about 2%, resulting in a calculated disease frequency of 1:10,000. However, the estimate is far more complicated because certain populations have high carrier rates of <italic toggle="yes">POLG</italic> alleles associated with AHS. For example, the frequency of the pathogenic allele p.Ala467Thr is 0.6% in Belgium and 1% in Norway. Other pathogenic alleles may have a founder effect; therefore, the incidence may vary by ethnicity.</p>
          <p>Pathogenic variants in <italic toggle="yes">POLG</italic>, identified as the cause of autosomal dominant PEO (adPEO) in nearly 50% of individuals in one series [<xref ref-type="bibr" rid="alpers.REF.lamantea.2002.211">Lamantea et al 2002</xref>], may be the most frequent cause of adPEO.</p>
        </sec>
      </sec>
      <sec id="alpers.Genetically_Related_Allelic_Disor">
        <title>Genetically Related (Allelic) Disorders</title>
        <p>Because the description of new <italic toggle="yes">POLG</italic> pathogenic variants is ongoing, knowledge of their associated phenotypes continues to evolve. <italic toggle="yes">POLG</italic> pathogenic variants have been shown to be associated with <related-object link-type="booklink" source-id="gene" document-id="cmt2" document-type="chapter">Charcot-Marie Tooth neuropathy type 2</related-object> [<xref ref-type="bibr" rid="alpers.REF.harrower.2008.133">Harrower et al 2008</xref>], <related-object link-type="booklink" source-id="gene" document-id="narp" document-type="chapter">Leigh syndrome</related-object> [<xref ref-type="bibr" rid="alpers.REF.naess.2009.484">Naess et al 2009</xref>, <xref ref-type="bibr" rid="alpers.REF.taanman.2009.248">Taanman et al 2009</xref>], and a MNGIE-like illness [<xref ref-type="bibr" rid="alpers.REF.tang.2012.862">Tang et al 2012</xref>] &#x02013; diseases that are generally associated with defects in other genes.</p>
        <p>Alterations in the CAG repeat region of <italic toggle="yes">POLG</italic> have been associated with idiopathic sporadic Parkinson disease [<xref ref-type="bibr" rid="alpers.REF.luoma.2007.1152">Luoma et al 2007</xref>] as well as <related-object link-type="booklink" source-id="gene" document-id="friedreich" document-type="chapter">Friedreich ataxia</related-object>, in which CAG repeat length was found to correlate inversely with age of onset [<xref ref-type="bibr" rid="alpers.REF.heidari.2008.489">Heidari et al 2008</xref>].</p>
      </sec>
      <sec id="alpers.Differential_Diagnosis">
        <title>Differential Diagnosis</title>
        <sec id="alpers.Epilepsia_Partialis_Continua">
          <title>Epilepsia Partialis Continua</title>
          <p>The frequency of epilepsia partialis continua in Alpers-Huttenlocher syndrome (AHS) suggests that unless a structural lesion is identified on neuroimaging, consideration for AHS as a cause is warranted [<xref ref-type="bibr" rid="alpers.REF.saneto.2010.140">Saneto et al 2010</xref>].</p>
        </sec>
        <sec id="alpers.Mitochondrial_DNA_Depletion_MDD_D">
          <title>Mitochondrial DNA Depletion (MDD) Disorders</title>
          <p>MDD disorders, characterized by a reduction in mtDNA copy number, have been associated with pathogenic variants in twelve nuclear genes: <italic toggle="yes">DGUOK, MPV17, POLG</italic>, <italic toggle="yes">RRM2B</italic>, <italic toggle="yes">SUCLA2</italic>, <italic toggle="yes">SUCLG1</italic>, <italic toggle="yes">TK2, TWNK</italic>, <italic toggle="yes">SLC25A4</italic>, <italic toggle="yes">FBXL4</italic>, <italic toggle="yes">MGME1,</italic> and <italic toggle="yes">TYMP</italic>. The gene products are involved either in mtDNA replication or in regulation of the mitochondrial deoxyribonucleoside triphosphate (dNTP) pools needed for mtDNA replication. Inheritance for all the MDD syndromes is autosomal recessive.</p>
          <p>MDD disorders may affect either a specific tissue (most commonly muscle or liver) or multiple organs, including the heart, brain, and kidney [<xref ref-type="bibr" rid="alpers.REF.ricci.1992.141">Ricci et al 1992</xref>]. MDD disorders need to be distinguished from the disorders of mtDNA mutation, duplication, or deletion (see <related-object link-type="booklink" source-id="gene" document-id="mt-overview" document-type="chapter">Mitochondrial Disorders Overview</related-object>).</p>
          <p>In one recent study in which 50 of 100 children with multiple electron transport chain defects had a mtDNA copy number lower than than 35% of normal controls, 18% of those with mtDNA depletion had <italic toggle="yes">DGUOK</italic> pathogenic variants and 18% had <italic toggle="yes">POLG</italic> pathogenic variants. Among those with mtDNA depletion and hepatic dysfunction, DGUOK deficiency was the most common single cause [<xref ref-type="bibr" rid="alpers.REF.sarzi.2007.531">Sarzi et al 2007</xref>].</p>
          <p><xref ref-type="table" rid="alpers.T.mitochondrial_dna_depletion_syn">Table 3</xref> summarizes the clinical phenotypes associated with pathogenic variants in these genes.</p>
          <p>Note: For some of the genes (<italic toggle="yes">POLG</italic> and <italic toggle="yes">TWNK</italic>), other phenotypes not associated with mtDNA depletion with autosomal dominant or recessive inheritance have been reported.</p>
          <table-wrap id="alpers.T.mitochondrial_dna_depletion_syn" orientation="portrait" position="anchor">
            <label>Table 3. </label>
            <caption>
              <p>Mitochondrial DNA Depletion Syndromes</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Gene</th>
                  <th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Phenotype</th>
                  <th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Function of Gene Product</th>
                  <th id="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Urinary Methylmalonic Acid</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">DGUOK</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hepatocerebral</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">MPV17</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hepatocerebral</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Unknown</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">POLG</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hepatocerebral/ AHS</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">mtDNA replication</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">RRM2B</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Encephalomyopathic with renal tubulopathy</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SUCLA2</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Encephalomyopathic</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SUCLG1</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Fatal infantile lactic acidosis</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">&#x02191;</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">TK2</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Myopathic</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1"><italic toggle="yes">TWNK</italic> (previously known as <italic toggle="yes">C10orf2</italic>)</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hepatocerebral</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">mtDNA replication</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Normal</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">SLC25A4</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Hypertrophic cardiomyopathy and exercise intolerance</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Adenine nucleotide, translocator, dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown/not reported&#x000a0;<sup>1</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">FBXL4</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Mitochondrial encephalopathy</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">F-box and leucine-rich repeat protein 4</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown/not reported&#x000a0;<sup>2,&#x000a0;3</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">MGME1</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Mitochondrial DNA depletion and multisystemic mitochondrial disease</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Exonuclease in mtDNA replication</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown/not reported&#x000a0;<sup>4</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">
                    <italic toggle="yes">TYMP</italic>
                  </td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">Mitochondrial neurogastrointestinal encephalopathy (MNGIE) syndrome</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">Thymidine phosphorylase, dNTP pools</td>
                  <td headers="hd_h_alpers.T.mitochondrial_dna_depletion_syn_1_1_1_4" valign="middle" align="left" rowspan="1" colspan="1">Unknown/not reported&#x000a0;<sup>1</sup></td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>dNTP = deoxyribonucleoside triphosphate</p>
              </fn>
              <fn>
                <p>mtDNA = mitochondrial DNA</p>
              </fn>
              <fn id="alpers.TF.3.1">
                <label>1. </label>
                <p>
                  <xref ref-type="bibr" rid="alpers.REF.christopher.2013.1136">Christopher &#x00026; Koshy [2013]</xref>
                </p>
              </fn>
              <fn id="alpers.TF.3.2">
                <label>2. </label>
                <p>
                  <xref ref-type="bibr" rid="alpers.REF.gai.2013.482">Gai et al [2013]</xref>
                </p>
              </fn>
              <fn id="alpers.TF.3.3">
                <label>3. </label>
                <p>
                  <xref ref-type="bibr" rid="alpers.REF.bonnen.2013.471">Bonnen et al [2013]</xref>
                </p>
              </fn>
              <fn id="alpers.TF.3.4">
                <label>4. </label>
                <p>
                  <xref ref-type="bibr" rid="alpers.REF.kornblum.2013.214">Kornblum et al [2013]</xref>
                </p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><related-object link-type="booklink" source-id="gene" document-id="dguok-mtddepl" document-type="chapter"><bold><italic toggle="yes">DGUOK</italic></bold></related-object><bold>.</bold> The two forms of deoxyguanosine kinase (DGUOK) deficiency are a hepatocerebral mitochondrial DNA depletion syndrome (multisystem disease in neonates) and isolated hepatic disease later in infancy or childhood. The majority of affected individuals have the multisystem illness with hepatic disease (cholestasis) and neurologic dysfunction evident within weeks of birth. They subsequently manifest severe hypotonia, developmental regression, and typical rotary nystagmus that evolves into opsoclonus. In contrast to AHS caused by <italic toggle="yes">POLG</italic> pathogenic variants, DGUOK deficiency is not characterized by seizures or brain imaging abnormalities [<xref ref-type="bibr" rid="alpers.REF.dimmock.2008.330">Dimmock et al 2008</xref>]. Those with isolated liver disease may also have renal involvement and some later develop mild hypotonia. Progressive hepatic disease is the most common cause of death in both forms. Reduced mtDNA copy number in liver or muscle can be used to confirm mtDNA depletion. Molecular genetic testing of <italic toggle="yes">DGUOK</italic> is necessary to establish the specific diagnosis of DGUOK deficiency [<xref ref-type="bibr" rid="alpers.REF.mandel.2001.337">Mandel et al 2001</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="mpv17-mtdep" document-type="chapter"><bold><italic toggle="yes">MPV17</italic></bold></related-object><bold>.</bold> Homozygosity for the <italic toggle="yes">MPV17</italic> pathogenic variant <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/NP_002428.1">NP_002428.1</ext-link>:p.Arg50Gln (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nuccore/NM_002437.4">NM_002437.4</ext-link>:c.149G&#x0003e;A) is associated with a mitochondrial DNA depletion syndrome displaying hepatic failure early in life: Navajo neurohepatopathy, a disorder found in the Navajo tribes in southwestern United States [<xref ref-type="bibr" rid="alpers.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>]. Navajo neurohepatopathy is characterized by the following [<xref ref-type="bibr" rid="alpers.REF.karadimas.2006.544">Karadimas et al 2006</xref>]:</p>
          <list list-type="bullet">
            <list-item>
              <p>Liver failure</p>
            </list-item>
            <list-item>
              <p>Severe sensory neuropathy</p>
            </list-item>
            <list-item>
              <p>Corneal anesthesia and scarring</p>
            </list-item>
            <list-item>
              <p>Cerebral leukoencephalopathy</p>
            </list-item>
            <list-item>
              <p>Failure to thrive</p>
            </list-item>
            <list-item>
              <p>Metabolic acidosis</p>
            </list-item>
          </list>
          <p>The function of <italic toggle="yes">MPV17</italic> is unknown but the protein has been shown to localize to mitochondria [<xref ref-type="bibr" rid="alpers.REF.spinazzola.2006.570">Spinazzola et al 2006</xref>]. Inheritance is autosomal recessive.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="rrm2b-mtddepl" document-type="chapter"><bold><italic toggle="yes">RRM2B</italic></bold></related-object><bold><italic toggle="yes">.</italic></bold> Mutation of <italic toggle="yes">RRM2B</italic> has been associated with severe muscle mtDNA depletion in several families [<xref ref-type="bibr" rid="alpers.REF.bourdon.2007.776">Bourdon et al 2007</xref>]. This disorder manifests as severe encephalopathy, myopathy with persistent lactic acidosis, hypotonia, renal tubular defects, seizures, respiratory distress, and diarrhea. Death occurs by age four months.</p>
          <p><italic toggle="yes">RRM2B</italic> encodes the p53-inducible small subunit of ribonucleotide reductase which comprises two subunits:</p>
          <list list-type="bullet">
            <list-item>
              <p>A large catalytic subunit, R1</p>
            </list-item>
            <list-item>
              <p>The smaller R2 subunit. Cells have two forms of the R2 subunit:</p>
              <list list-type="bullet">
                <list-item>
                  <p>A cell cycle-regulated form that is maximally expressed in S-phase;</p>
                </list-item>
                <list-item>
                  <p>A p53-inducible form known as p53R2. The p53R2 form is required for a basal level of DNA repair and mtDNA synthesis in non-proliferating cells.</p>
                </list-item>
              </list>
            </list-item>
          </list>
          <p>Ribonucleotide reductase activity is required to produce the nucleotide precursors required for DNA replication by reduction of ribonucleoside diphosphates to deoxyribonucleoside diphosphates.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="sucla2-def" document-type="chapter"><bold><italic toggle="yes">SUCLA2</italic></bold></related-object><bold>.</bold>
<italic toggle="yes">SUCLA2</italic>-related mitochondrial DNA depletion syndrome, encephalomyopathic form, with mild methylmalonic aciduria is characterized by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Onset of severe hypotonia in early infancy (birth to 5 months)</p>
            </list-item>
            <list-item>
              <p>Severe muscular atrophy with failure to achieve independent ambulation</p>
            </list-item>
            <list-item>
              <p>Progressive scoliosis or kyphosis</p>
            </list-item>
            <list-item>
              <p>Dystonia and/or hyperkinesias (i.e., athetoid or choreiform movements)</p>
            </list-item>
            <list-item>
              <p>Epilepsy (infantile spasms or generalized convulsions with onset from birth to 3 years) in a few children</p>
            </list-item>
            <list-item>
              <p>Postnatal growth retardation</p>
            </list-item>
            <list-item>
              <p>Severe sensorineural hearing impairment</p>
            </list-item>
          </list>
          <p>The outcome is poor with early lethality. Metabolic findings usually include urinary excretion of methylmalonic acid (MMA), elevated plasma methylmalonic acid concentration, and elevated plasma lactate concentration. Plasma carnitine ester profiling shows increased C3-carnitine and C4-dicarboxylic-carnitine. Urinary excretion of C4-dicarboxylic carnitine is usually approximately 20 times normal. CT/MRI may show central and cortical atrophy, bilateral basal ganglia involvement (mainly the putamen and caudate nuclei), and delayed myelination. <italic toggle="yes">SUCLA2</italic> is the only gene known to be associated with this disorder [<xref ref-type="bibr" rid="alpers.REF.elpeleg.2005.1081">Elpeleg et al 2005</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="suclg1-mtddepl" document-type="chapter"><bold><italic toggle="yes">SUCLG1</italic></bold></related-object><bold>.</bold> Pathogenic variants have been reported in <italic toggle="yes">SUCLG1</italic>, which encodes the &#x003b1; subunit of succinate-CoA ligase [<xref ref-type="bibr" rid="alpers.REF.ostergaard.2007.383">Ostergaard et al 2007</xref>]. Affected individuals show the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Urinary excretion of MMA</p>
            </list-item>
            <list-item>
              <p>Combined respiratory chain enzyme deficiency</p>
            </list-item>
            <list-item>
              <p>Mitochondrial DNA depletion</p>
            </list-item>
          </list>
          <p>The phenotype may be indistinguishable from <italic toggle="yes">SUCLA2</italic>-related mitochondrial DNA depletion syndrome, encephalomyopathic form, with mild methylmalonic aciduria [<xref ref-type="bibr" rid="alpers.REF.ostergaard.2010.201">Ostergaard et al 2010</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="tk2-mtddepl" document-type="chapter"><bold><italic toggle="yes">TK2</italic></bold></related-object><bold>.</bold> Mitochondrial myopathy with mtDNA depletion is caused by pathogenic variants in <italic toggle="yes">TK2</italic>, the gene encoding thymidine kinase [<xref ref-type="bibr" rid="alpers.REF.saada.2001.342">Saada et al 2001</xref>].</p>
          <p><bold><italic toggle="yes">SLC25A4.</italic></bold> Autosomal recessive mitochondrial DNA depletion syndrome is caused by biallelic pathogenic variants in <italic toggle="yes">SLC25A4</italic>, the gene encoding the adenine nucleotide translocator, ANT1 [<xref ref-type="bibr" rid="alpers.REF.palmieri.2005.3079">Palmieri et al 2005</xref>]. Affected individuals may present with the SANDO (ANS) phenotype [<xref ref-type="bibr" rid="alpers.REF.hanisch.2014">Hanisch et al 2014</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="fbxl4-mtddepl" document-type="chapter"><bold><italic toggle="yes">FBXL4</italic></bold></related-object><bold><italic toggle="yes">.</italic></bold> Mitochondrial encephalopathy with mtDNA depletion is caused by pathogenic variants in <italic toggle="yes">FBXL4</italic>, the gene encoding F-box/LRR-repeat protein 4 [<xref ref-type="bibr" rid="alpers.REF.bonnen.2013.471">Bonnen et al 2013</xref>, <xref ref-type="bibr" rid="alpers.REF.gai.2013.482">Gai et al 2013</xref>]. Children from three unrelated Arabian families who presented with a fatal encephalopathy, lactic acidosis, and severe depletion in muscle mtDNA were identified to have compound pathogenic heterozygous nonsense and splicing variants in <italic toggle="yes">FBXL4</italic>. The children presented between birth and age six years, and (except for the child age 6 years, who was alive at the time of the report) died between a few days after diagnosis and age four years. Most of the affected individuals had developmental delay. <italic toggle="yes">FBXL4</italic> is an F-box protein that colocalizes in the mitochondria and causes a respiratory chain deficiency, loss of mitochondrial membrane potential, and a disturbance of the dynamic mitochondrial network and nucleoid distribution in fibroblasts from affected individuals.</p>
          <p><bold><italic toggle="yes">MGME1.</italic></bold> Mitochondrial DNA depletion syndrome results from biallelic pathogenic variants in <italic toggle="yes">MGME1,</italic> the gene encoding mitochondrial genome maintenance exonuclease 1, a mitochondrial RecB-type exonuclease [<xref ref-type="bibr" rid="alpers.REF.kornblum.2013.214">Kornblum et al 2013</xref>]. Individuals present between ages ten and 36 years with ptosis, followed by mild PEO, diffuse skeletal muscle wasting and myopathy, profound emaciation, and respiratory failure. Intellectual disability was found in only one family of three affected individuals.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="mngie" document-type="chapter"><bold>Mitochondrial neurogastrointestinal encephalopathy</bold></related-object>
<bold>(MNGIE)</bold> is characterized by the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Progressive gastrointestinal dysmotility and cachexia</p>
            </list-item>
            <list-item>
              <p>Ptosis/ophthalmoplegia or ophthalmoparesis</p>
            </list-item>
            <list-item>
              <p>Hearing loss</p>
            </list-item>
            <list-item>
              <p>Demyelinating peripheral neuropathy manifesting as paresthesias and symmetric and distal weakness primarily in the lower extremities</p>
            </list-item>
          </list>
          <p>Onset is usually between the first and fifth decades; in about 60% of individuals, symptoms begin before age 20 years. Diagnosis is based on the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Plasma thymidine concentration greater than 3 &#x000b5;mol/L</p>
            </list-item>
            <list-item>
              <p>Plasma deoxyuridine concentration greater than 5 &#x000b5;mol/L</p>
            </list-item>
            <list-item>
              <p>Thymidine phosphorylase enzyme activity in leukocytes less than 10% of controls</p>
            </list-item>
            <list-item>
              <p>Molecular genetic testing of <italic toggle="yes">TYMP</italic> (previously known as <italic toggle="yes">ECGF1</italic>), the only gene known to be associated with canonical MNGIE disease with elevated thymidine levels in the serum [<xref ref-type="bibr" rid="alpers.REF.nishino.1999.689">Nishino et al 1999</xref>]</p>
              <p>Note: Several MNGIE-like disorders associated with pathogenic variants in <italic toggle="yes">POLG</italic> and mtDNA (e.g., m.3243A&#x0003e;G) have been described.</p>
            </list-item>
          </list>
        </sec>
        <sec id="alpers.Other_Disorders_to_Consider">
          <title>Other Disorders to Consider</title>
          <p><bold>Autosomal dominant progressive external ophthalmoplegia (adPEO)</bold> is caused by mutation of one of the following genes:</p>
          <list list-type="bullet">
            <list-item>
              <p><italic toggle="yes">SLC25A4</italic> (previously known as <italic toggle="yes">ANT1</italic>), the gene encoding the heart/skeletal muscle isoform of adenine nucleotide translocator [<xref ref-type="bibr" rid="alpers.REF.kaukonen.2000.782">Kaukonen et al 2000</xref>]</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">TWNK</italic> (previously known as <italic toggle="yes">C10orf2</italic>) encoding twinkle, which is responsible for mtDNA integrity [<xref ref-type="bibr" rid="alpers.REF.spelbrink.2001.223">Spelbrink et al 2001</xref>]</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">OPA1,</italic> which affects mitochondrial fusion and fission [<xref ref-type="bibr" rid="alpers.REF.amatibonneau.2008.338">Amati-Bonneau et al 2008</xref>, <xref ref-type="bibr" rid="alpers.REF.hudson.2008.329">Hudson et al 2008</xref>]</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">POLG2</italic>, which codes for the accessory subunit of polymerase gamma [<xref ref-type="bibr" rid="alpers.REF.longley.2006.1026">Longley et al 2006</xref>]</p>
            </list-item>
            <list-item>
              <p><italic toggle="yes">POLG</italic>, encoding DNA polymerase gamma, which is responsible for mtDNA replication [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>]</p>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="opmd" document-type="chapter"><bold>Oculopharyngeal muscular dystrophy</bold></related-object> with onset usually after age 45 years may result in progressive ptosis and bulbar dysfunction manifest as swallowing difficulty. This disorder may mimic the clinical manifestations of the <italic toggle="yes">POLG</italic>-related disorders in which PEO is the predominant feature.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="amish-mcph" document-type="chapter"><bold>Amish lethal microcephaly</bold></related-object> is characterized by microcephaly and early death. The occipitofrontal circumference is typically six to 12 SD below the mean; anterior and posterior fontanels are closed at birth and facial features are distorted. The average life span is between five and six months. Diagnosis is based on a tenfold increase in the levels of the urinary organic acid 2-ketoglutarate. <italic toggle="yes">SLC25A19</italic> (also known as <italic toggle="yes">DNC</italic> or <italic toggle="yes">MUP1</italic>), encoding the mitochondrial deoxynucleotide carrier [<xref ref-type="bibr" rid="alpers.REF.rosenberg.2002.175">Rosenberg et al 2002</xref>], is the only gene known to be associated with Amish lethal microcephaly. All affected individuals within the Old Order Amish population are homozygous for the same single-base pair substitution.</p>
          <p><bold>Chronic progressive external ophthalmoplegia (CPEO)</bold> in a simplex case or when there is a maternal family history can be the result of a large-scale single deletion of mtDNA which may only be detected in limited tissues (e.g., skeletal muscle). CPEO is sometimes complicated by mild proximal muscle weakness and dysphagia, and can be considered to lie on a spectrum of disease from pure CPEO to the Kearns-Sayre syndrome. Some individuals with CPEO (&#x0003c;20%) have a pathogenic single-nucleotide variant of mitochondrial DNA (e.g., m.3243A&#x0003e;G).</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="kss" document-type="chapter"><bold>Kearns-Sayre syndrome</bold></related-object>
<bold>(KSS)</bold> is a multisystem disorder defined by the following triad:</p>
          <list list-type="bullet">
            <list-item>
              <p>Onset before age 20 years</p>
            </list-item>
            <list-item>
              <p>Pigmentary retinopathy</p>
            </list-item>
            <list-item>
              <p>PEO</p>
            </list-item>
          </list>
          <p>In addition, affected individuals have <bold>at least one</bold> of the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Cardiac conduction block</p>
            </list-item>
            <list-item>
              <p>Cerebrospinal fluid protein concentration greater than 100 mg/dL</p>
            </list-item>
            <list-item>
              <p>Cerebellar ataxia</p>
            </list-item>
          </list>
          <p>Onset is usually in childhood. PEO, characterized by ptosis, paralysis of the extraocular muscles (ophthalmoplegia), and variably severe proximal limb weakness, is relatively benign. Mitochondrial DNA deletion syndromes are caused by mtDNA deletions ranging in size from two to ten kilobases. Approximately 90% of individuals with KSS have a large-scale (i.e., 1.1-10 kb) mtDNA deletion that is usually present in all tissues; however, mutated mtDNA is often undetectable in blood cells, necessitating examination of muscle. When inherited, mtDNA deletion syndromes are transmitted by maternal inheritance. The mother of a proband with a mtDNA deletion syndrome is usually unaffected and does not have mtDNA deletions in her tissues; therefore, the risk to the sibs of a proband is usually extremely low. Offspring of females with KSS are usually not at risk of inheriting the pathogenic variant; however, exceptions occur.</p>
          <p><bold>Mutation of <italic toggle="yes">BCS1L</italic></bold> is associated with</p>
          <list list-type="bullet">
            <list-item>
              <p>GRACILE syndrome (<italic toggle="yes">g</italic>rowth <italic toggle="yes">r</italic>etardation, <italic toggle="yes">a</italic>minoaciduria, <italic toggle="yes">c</italic>holestasis, <italic toggle="yes">i</italic>ron overload, <italic toggle="yes">l</italic>actic acidosis, and <italic toggle="yes">e</italic>arly death) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603358">603358</ext-link>);</p>
            </list-item>
            <list-item>
              <p>Bj&#x000f8;rnstad syndrome (congenital profound hearing loss and <italic toggle="yes">pili torti</italic>) (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/262000">262000</ext-link>);</p>
            </list-item>
            <list-item>
              <p>An overlapping GRACILE syndrome-Bj&#x000f8;rnstad syndrome phenotype.</p>
            </list-item>
          </list>
          <p>Children with the pure form of Bj&#x000f8;rnstad syndrome have normal intellect. The BCS1L protein is an assembly factor for complex III responsible for insertion of the Fe-S core into the complex. Affected children have a biochemical defect in complex III. The clinical scenario of a hepato-encephalopathy may appear similar to AHS at a single point in time, but mtDNA depletion is not part of the pathology described in those with <italic toggle="yes">BCS1L</italic> pathogenic variants.</p>
          <p><bold><italic toggle="yes">SCO1</italic></bold> (OMIM <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://omim.org/entry/603644">603644</ext-link>). Hepatic failure and severe encephalopathy have also been associated with compound heterozygosity for two pathogenic variants in <italic toggle="yes">SCO1</italic>.</p>
          <p><bold>Other.</bold> The differential diagnosis of MDD disorders also includes infantile or late-infantile progressive encephalopathies with primary involvement of cortical gray matter and refractory epilepsy.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="ncl" document-type="chapter"><bold>Neuronal ceroid-lipofuscinoses</bold></related-object>
<bold>(NCLs)</bold> are a group of inherited, neurodegenerative, lysosomal storage disorders characterized by progressive mental and motor deterioration, seizures, and early death. Visual loss is a feature of most forms. Phenotypes included in the NCLs that overlap with AHS are: infantile neuronal ceroid-lipofuscinosis (INCL, Santavuori-Haltia) and late-infantile (LINCL, Jansk&#x000fd;-Bielschowsky). Inheritance is autosomal recessive.</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>INCL.</bold> Children with INCL are normal at birth; symptoms usually present acutely between ages six and 24 months. Initial signs include delayed development, myoclonic jerks and/or seizures, deceleration of head growth, and specific EEG changes. Affected infants develop retinal blindness and seizures by age two years, followed by progressive mental deterioration. Mutation of <italic toggle="yes">PPT1</italic> is causative.</p>
            </list-item>
            <list-item>
              <p><bold>LINCL.</bold> The first symptoms of LINCL typically appear between age two and four years, usually starting with epilepsy, followed by regression of developmental milestones, dementia, ataxia, and extrapyramidal and pyramidal signs. Visual impairment typically appears between ages four and six years and rapidly progresses to blindness. Life expectancy ranges from age six years to greater than age 40 years. Mutation of <italic toggle="yes">PPT1</italic> (encoding the enzyme palmitoyl-protein thioesterase 1), <italic toggle="yes">TPP1</italic> (encoding the enzyme tripeptidyl-peptidase 1), <italic toggle="yes">CLN5</italic>, <italic toggle="yes">CLN6</italic>, and <italic toggle="yes">CLN8</italic> can be causative.</p>
            </list-item>
          </list>
          <p><related-object link-type="booklink" source-id="gene" document-id="merrf" document-type="chapter"><bold>MERRF</bold></related-object> (<italic toggle="yes">m</italic>yoclonic <italic toggle="yes">e</italic>pilepsy associated with <italic toggle="yes">r</italic>agged <italic toggle="yes">r</italic>ed <italic toggle="yes">f</italic>ibers) is a multisystem disorder characterized by myoclonus, which is often the first symptom, followed by generalized epilepsy, ataxia, weakness, and dementia. Onset is usually in childhood, occurring after normal early development. Common findings are hearing loss, short stature, optic atrophy, and cardiomyopathy with Wolff-Parkinson-White (WPW) syndrome. Occasionally pigmentary retinopathy and lipomatosis are observed. MERRF is transmitted by maternal inheritance.</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter"><bold>MELAS</bold></related-object> (<italic toggle="yes">m</italic>itochondrial <italic toggle="yes">e</italic>ncephalomyopathy, <italic toggle="yes">l</italic>actic <italic toggle="yes">a</italic>cidosis, and <italic toggle="yes">s</italic>trokelike episodes) is a multisystem disorder with onset typically occurring in childhood. Early psychomotor development is usually normal. Onset of symptoms is often between ages two and ten years. The most common initial symptoms are generalized tonic-clonic seizures, recurrent headaches, anorexia, and recurrent vomiting. Seizures are often associated with stroke-like episodes of transient hemiparesis or cortical blindness. The cumulative residual effects of the stroke-like episodes gradually impair motor abilities, vision, and mentation, often by adolescence or young adulthood. Sensorineural hearing loss is common. MELAS is transmitted by maternal inheritance.</p>
          <p><bold>Storage diseases</bold> during infancy and early childhood, such as atypical <related-object link-type="booklink" source-id="gene" document-id="tay-sachs" document-type="chapter">hexosaminidase A deficiency</related-object>, Sandhoff disease, infantile sialidosis, and galactosialidosis, can be diagnosed by testing for lysosomal enzyme activity in the appropriate tissue.</p>
          <p><bold>Other rare neonatal-onset causes</bold> of a progressive encephalopathy with refractory seizures include <related-object link-type="booklink" source-id="gene" document-id="pds" document-type="chapter">pyridoxine-dependent seizures</related-object>, cerebral folate deficiency, <related-object link-type="booklink" source-id="gene" document-id="nkh" document-type="chapter">glycine encephalopathy</related-object> (also known as nonketotic hyperglycinemia), <related-object link-type="booklink" source-id="gene" document-id="biotin" document-type="chapter">biotinidase deficiency</related-object>, and disorders of biogenic amine metabolism, such as folate-responsive seizures. Pyridoxine-dependent seizures and biotinidase deficiency are treatable and on occasion reversible [<xref ref-type="bibr" rid="alpers.REF.wolf.2005.441">Wolf 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.gallagher.2009.550">Gallagher et al 2009</xref>].</p>
          <p><related-object link-type="booklink" source-id="gene" document-id="iso-def" document-type="chapter"><bold>Sulfite oxidase deficiency</bold></related-object> and <bold>Menkes disease</bold> (see <related-object link-type="booklink" source-id="gene" document-id="menkes" document-type="chapter"><italic toggle="yes">ATP7A</italic>-Related Copper Transport Disorders</related-object>) usually present earlier in infancy. Sulfite oxidase deficiency can be screened for using a commercially available sulfite oxidase urine dipstick test and Menkes disease by detecting low serum concentrations of copper and ceruloplasmin. Current molecular genetic testing can detect pathogenic variants in <italic toggle="yes">ATP7A,</italic> the only gene known to be associated with Menkes disease, in more than 95% of affected individuals. Inheritance of Menkes disease is X-linked.</p>
          <p><bold>Slow virus diseases</bold> (subacute sclerosing panencephalitis) are extremely rare at this age.</p>
          <p>Within the differential diagnosis are also <bold>epileptic syndromes</bold> that appear to be progressive at the onset but that usually plateau into developmental arrest/delay.</p>
          <p>The <bold>channelopathies</bold> are with a group of severe infantile epileptic disorders caused by mutation of <italic toggle="yes">SCN1A</italic>, <italic toggle="yes">SCN91</italic>, <italic toggle="yes">CACNB4</italic>, <italic toggle="yes">or CACNA1A</italic>, which encode for sodium and calcium channels. See <related-object link-type="booklink" source-id="gene" document-id="gefs" document-type="chapter"><italic toggle="yes">SCN1A</italic>-Related Seizure Disorders</related-object>.</p>
          <p>Both <bold>myoclonic epilepsy</bold> and the <bold>Lennox-Gastaut syndrome</bold> can cause dementia or pseudo-dementia as a result of unrelenting seizures and anticonvulsant side effects.</p>
        </sec>
      </sec>
      <sec id="alpers.Management">
        <title>Management</title>
        <sec id="alpers.Evaluations_Following_Initial_Dia">
          <title>Evaluations Following Initial Diagnosis</title>
          <p>To establish the extent of disease and needs in an individual diagnosed with a <italic toggle="yes">POLG</italic>-related disorder, evaluation should always include measures of functional neurologic status.</p>
          <p>In order to determine the baseline function for a given affected individual, it is reasonable to conduct the following evaluations as appropriate for the phenotypic presentation:</p>
          <list list-type="bullet">
            <list-item>
              <p>Electroencephalogram (EEG) and video EEG monitoring</p>
            </list-item>
            <list-item>
              <p>Formal developmental assessment to provide a baseline of function as well as offer insights into the need for occupational, physical, and/or speech therapy</p>
            </list-item>
            <list-item>
              <p>Brain MRI. On occasion the first neuroimaging study may be normal, but with certain phenotypes, such as AHS, changes may be seen in a relatively short amount of time.</p>
            </list-item>
            <list-item>
              <p>Electrocardiogram. If a mitochondrial illness is suspected and if there is not yet genetic confirmation of a <italic toggle="yes">POLG</italic> disease it is reasonable to consider both electrocardiogram and echocardiogram.</p>
            </list-item>
            <list-item>
              <p>Formal assessment of vision and hearing</p>
            </list-item>
            <list-item>
              <p>Swallowing study, if bulbar signs are present</p>
            </list-item>
            <list-item>
              <p>Nutritional assessment</p>
            </list-item>
            <list-item>
              <p>Baseline pulmonary function testing</p>
            </list-item>
            <list-item>
              <p>Sleep polysomnogram specifically for the purpose of evaluating for central or obstructive apnea or hypopnea that result in either pCO<sub>2</sub> elevation or O<sub>2</sub> desaturation</p>
            </list-item>
            <list-item>
              <p>Liver function tests including fasting serum glucose concentration, ALT, and AST; serum concentrations of ammonia, glutamine and tyrosine (found in an amino acid panel), bilirubin, albumin, and cholesterol; and the coagulation factors (prothrombin time or INR). Liver ultrasound examination may assist in determining the presence of fibrosis.</p>
              <p>Note: AST elevation, and to a lesser extent ALT elevation, may be due to muscle disease; simultaneously obtaining a serum CK level differentiates between liver and muscle involvement, although both liver and muscle disease can be seen in individuals with <italic toggle="yes">POLG</italic>-related disorders.</p>
            </list-item>
            <list-item>
              <p>Clinical genetics consultation</p>
            </list-item>
          </list>
        </sec>
        <sec id="alpers.Treatment_of_Manifestations">
          <title>Treatment of Manifestations</title>
          <p>Treatment is limited to symptom management and supportive care.</p>
          <sec id="alpers.AlpersHuttenlocher_Syndrome">
            <title>Alpers-Huttenlocher Syndrome</title>
            <p><bold>Family education</bold> is critical. It is important to address the quality of life/intensity of treatment issues frequently and when major changes occur in disease status. Once the family has started the process of accepting the diagnosis, it is important to involve the family with options for supportive care that can be offered as the illness progresses. These will include (but are not limited to) the use of a gastrostomy feeding tube and the different levels of artificial ventilation that could include less invasive treatments such as CPAP or BiPAP, assisted nasal ventilation, and/or intubation, and the use of a tracheostomy and ventilator. Involvement of palliative care services can assist the care team in these discussions, as well as in practical aspects of implementation. Although rehabilitative services are a necessary part of the treatment and care plan for these children, and rehabilitation units are often where parents of children with new gastrostomy tubes and ventilator support learn to care for their children, the global perspective of care should be palliative even if death is not imminent.</p>
            <p><bold>Supportive therapies.</bold> Occupational, physical, and/or speech therapy is indicated to maintain neurologic function for as long as possible and to insure comfort when deterioration begins.</p>
            <p><bold>Gastrointestinal.</bold> A consult with a gastroenterologist regarding feeding or nutritional issues, or evidence of liver involvement may be appropriate. Surgical placement of a gastric feeding tube when appropriate can maintain nutritional status and/or prevent aspiration of oral feeding.</p>
            <p><bold>Hepatic.</bold> Standard treatment for liver failure may include small frequent meals or continuous feeding to compensate for defective gluconeogenesis, reduction in dietary protein to a minimum, use of non-absorbable sugars to create an osmotic diarrhea, and use of conjugating agents to treat hyperammonemia.</p>
            <p>Because levocarnitine may have some benefit in the setting of liver failure and because of its low toxicity, some recommend its use from the time of diagnosis.</p>
            <p><bold>Respiratory.</bold> Tracheostomy placement and artificial ventilation may be performed, as appropriate.</p>
            <p>Assessment of nocturnal ventilatory function can be performed for evidence of central and/or obstructive apnea using polysomnography with measurement of pCO<sub>2</sub> and monitoring by pulse oximetry. Treatment with CPAP or BiPAP as indicated is appropriate.</p>
            <p><bold>Seizures.</bold> Seizure control is a goal of treatment; however, refractory epilepsy, especially epilepsia partialis continua (EPC), may be impossible to control with any treatment. In individuals with EPC, the use of high-dose anticonvulsants may control the clinical seizures, but the associated obtundation with subsequent risk of aspiration and ventilatory failure may outweigh the benefit.</p>
            <p>Although anticonvulsant monotherapy is preferred, treatment with more than one medication often becomes necessary as the child&#x02019;s seizures worsen and as multiple types of seizures occur. If high-dose anticonvulsant therapy is not effective in improving the quality of life by reducing the seizure burden, reducing the number and/or dose of medications may improve quality of life by reducing medication side-effects.</p>
            <p>There is no evidence that newer anticonvulsants such as felbamate, lamotrigine, topiramate, oxcarbazepine, or levetiracetam offer a better therapeutic benefit over the older medications (phenobarbital, phenytoin, carbamazepine, primidone); however, the newer medications tend to be less sedating, may require less processing by the liver, and have fewer drug-drug interactions. Intravenous magnesium, used most often to treat seizures in eclampsia, has shown efficacy in one report where affected individuals with status epilepicus were refractory to other typical anticonvulsants [<xref ref-type="bibr" rid="alpers.REF.visser.2011.218">Visser et al 2011</xref>].</p>
            <p>One unpublished pathway for management of seizures is to begin with lamotrigine monotherapy, and when this is no longer effective for adequate control of seizures, add lacosamide. Adding clobazam may also help when these medications are no longer effective [RP Saneto, personal communication]. With the exception of valproate (see Note), other standard anticonvulsants are reasonable to use, although medications that are heavily metabolized by the liver, such as phenytoins or the barbiturates, should be reserved until other medications fail.</p>
            <p>Note: Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) should be avoided (see <xref ref-type="sec" rid="alpers.AgentsCircumstances_to_Avoid">Agents/Circumstances to Avoid</xref>). Because other anticonvulsants have also been implicated in accelerating liver deterioration, it is reasonable to monitor liver enzymes every two to four weeks after introducing any new anticonvulsant [Bicknese et al1992].</p>
            <p><bold>Movement disorder.</bold> In addition to electroencephalographic seizures, myoclonus and other non-epileptic movement disorders occur as part of AHS and can be as disabling as seizures. These movements should not be confused with seizures, and video EEG is often the only way to differentiate a seizure from a non-epileptic movement disorder. The use of benzodiazepines often reduces the severity of these abnormal movements and also assists in seizure management and reduction of spasticity.</p>
            <p>Chorea and athetosis [<xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al 2005</xref>] may cause pain, and treatment with muscle relaxants and pain medications, including narcotics, would be advised. Some movement disorders can be treated with dopaminergic medication such as levodopa-carbidopa or tetrabenazine: a trial of either of these medications can be considered.</p>
            <p>In most cases, not all seizures and/or non-epileptic movements can be suppressed with medication, and a balance between the adverse effects of the medication(s) and the disability created by the seizures or movements must be accepted by both the family and physician. Often a modest reduction in seizure control is offset by an improved level of alertness, although the benefit may not be lasting.</p>
          </sec>
          <sec id="alpers.Other_Phenotypes">
            <title>Other Phenotypes</title>
            <p>Management is supportive and involves conventional approaches such as physiotherapy, speech therapy, and seizure management.</p>
            <p>Gastrostomy may be required to provide adequate nutrition.</p>
            <p>Surgery for ptosis may provide symptomatic relief for some.</p>
          </sec>
        </sec>
        <sec id="alpers.Prevention_of_Secondary_Complicat">
          <title>Prevention of Secondary Complications</title>
          <p>For individuals with any of the <italic toggle="yes">POLG</italic>-related phenotypes, dose reduction in medications metabolized by hepatic enzymes may be necessary to avoid toxicity.</p>
          <p>Reports suggest that CSF folate may be deficient in disorders that lead to mtDNA depletion [<xref ref-type="bibr" rid="alpers.REF.hasselmann.2010.58">Hasselmann et al 2010</xref>]. Therefore, testing for CSF folate deficiency and offering treatment to those with deficiency is one option; the other option is empiric therapy with folinic acid (calcium leucovorin).</p>
        </sec>
        <sec id="alpers.Surveillance">
          <title>Surveillance</title>
          <p>Individuals with <italic toggle="yes">POLG</italic>-related disorders require frequent examination and interval evaluation by a team comprising the following:</p>
          <list list-type="bullet">
            <list-item>
              <p>Primary care provider</p>
            </list-item>
            <list-item>
              <p>Neurologist</p>
            </list-item>
            <list-item>
              <p>Clinical geneticist</p>
            </list-item>
            <list-item>
              <p>Hepatologist or gastroenterologist</p>
            </list-item>
            <list-item>
              <p>Physiatrist</p>
            </list-item>
            <list-item>
              <p>Psychiatrist</p>
            </list-item>
            <list-item>
              <p>Ophthalmologist</p>
            </list-item>
            <list-item>
              <p>Pulmonologist</p>
            </list-item>
          </list>
          <p><bold>Laboratory tests.</bold> No standard of care guidelines are available to suggest the frequency for which the following tests should be obtained. Testing should be guided by clinical features and the proposed schedule should be modified if the clinical course is stable. For those with the most severe phenotypes, the following could be considered:</p>
          <list list-type="bullet">
            <list-item>
              <p><bold>Every three months.</bold> CBC; electrolytes, liver enzymes (AST, ALT, GGT); CK, liver function tests including: preprandial serum glucose concentration; serum concentration of ammonia, albumin, bilirubin (free and conjugated), and cholesterol; and prothrombin time or INR as a measure of coagulation factors</p>
            </list-item>
            <list-item>
              <p><bold>Annually.</bold> Urine analysis; serum concentration of lactic acid</p>
            </list-item>
            <list-item>
              <p><bold>Biannually.</bold> Plasma amino acids; urine organic acids; plasma concentration of free and total carnitine (unless treated with levocarnitine, in which case measure annually)</p>
            </list-item>
          </list>
          <p>
            <bold>Imaging and diagnostic procedures</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Liver ultrasound examination annually</p>
            </list-item>
            <list-item>
              <p>EEG and video EEG monitoring (e.g., for suspicion of subclinical status epilepticus; presence of epilepsia partialis continua; need to determine if events are seizures or non-epileptic movements)</p>
            </list-item>
            <list-item>
              <p>Audiogram and brain stem auditory evoked responses as clinically indicated</p>
            </list-item>
            <list-item>
              <p>Barium swallow study as clinically indicated</p>
            </list-item>
            <list-item>
              <p>Polysomnogram with CPAP titration as part of an evaluation of subacute mental status changes or every two to three years</p>
            </list-item>
          </list>
        </sec>
        <sec id="alpers.AgentsCircumstances_to_Avoid">
          <title>Agents/Circumstances to Avoid</title>
          <p>Valproic acid (Depakene<sup>&#x000ae;</sup>) and sodium divalproate (divalproex) (Depakote<sup>&#x000ae;</sup>) should be avoided because of the risk of precipitating and/or accelerating liver disease [<xref ref-type="bibr" rid="alpers.REF.bicknese.1992.767">Bicknese et al 1992</xref>, <xref ref-type="bibr" rid="alpers.REF.saneto.2010.140">Saneto et al 2010</xref>].</p>
          <p>As with some other mitochondrial diseases, physical stressors such as infection, fever, dehydration, and anorexia can result in a sudden deterioration and should be avoided as much as possible.</p>
        </sec>
        <sec id="alpers.Evaluation_of_Relatives_at_Risk">
          <title>Evaluation of Relatives at Risk</title>
          <p>See <xref ref-type="sec" rid="alpers.Related_Genetic_Counseling_Issues">Genetic Counseling</xref> for issues related to testing of at-risk relatives for genetic counseling purposes.</p>
        </sec>
        <sec id="alpers.Therapies_Under_Investigation">
          <title>Therapies Under Investigation</title>
          <p>Search <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link> for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p>
        </sec>
        <sec id="alpers.Other">
          <title>Other</title>
          <p>Liver transplantation is not advised in children with AHS because transplanting the liver does not alter the rapid progression of the brain disease [<xref ref-type="bibr" rid="alpers.REF.kelly.2000.170">Kelly 2000</xref>].</p>
          <p>However, liver transplantation in adults who have an acceptable quality of life may be of benefit.</p>
          <list list-type="bullet">
            <list-item>
              <p>In one report, one of two individuals undergoing liver transplantation survived [<xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>].</p>
            </list-item>
            <list-item>
              <p>In another report, a woman underwent liver transplantation at age 19 years, eight years after experiencing fulminant hepatic failure following onset of valproate therapy. Molecular genetic testing seven years after her liver transplantation confirmed the diagnosis of a <italic toggle="yes">POLG</italic>-related disorder; her phenotype fit best with SANDO [<xref ref-type="bibr" rid="alpers.REF.wong.2008.e150">Wong et al 2008</xref>]. As of late 2012 (15 years after liver transplantation), she was alive and living semi-independently, albeit with progressive central nervous system dysfunction, specifically failing memory with increasing chorea and hemiballismus.</p>
            </list-item>
          </list>
          <p>The use of other treatments for refractory epilepsy, such as corticotropin or prednisone, ketogenic diet, and intravenous IgG, are unproven in the treatment of AHS.</p>
          <list list-type="bullet">
            <list-item>
              <p>Vitamin and cofactor therapy with the intent to fortify mitochondrial function may be offered. There have not been formal studies of the use of these vitamins and cofactors in AHS or other <italic toggle="yes">POLG</italic>-related disorders [<xref ref-type="bibr" rid="alpers.REF.parikh.2009.414">Parikh et al 2009</xref>].</p>
            </list-item>
            <list-item>
              <p>The use of folinic acid should be strongly considered (see <xref ref-type="sec" rid="alpers.Prevention_of_Secondary_Complicat">Prevention of Secondary Complications</xref>).</p>
            </list-item>
            <list-item>
              <p>The use of levo-arginine has been reported helpful in reducing the frequency and severity of the strokes associated with <related-object link-type="booklink" source-id="gene" document-id="melas" document-type="chapter">MELAS</related-object>, and can be considered for use in persons with <italic toggle="yes">POLG</italic>-related disorders, especially if deficiency in the plasma or CSF arginine concentration is confirmed.</p>
            </list-item>
            <list-item>
              <p>Levocarnitine, creatine monohydrate, coenzyme Q<sub>10</sub>, B vitamins, and antioxidants such as alpha lipoic acid, vitamin E, and vitamin C have been used as mitochondrial supplements. Use of all in <italic toggle="yes">POLG</italic>-related disorders is reasonable based on limited published evidence and their general lack of toxicity [<xref ref-type="bibr" rid="alpers.REF.gold.2001.309">Gold &#x00026; Cohen 2001</xref>, <xref ref-type="bibr" rid="alpers.REF.rodriguez.2007.235">Rodriguez et al 2007</xref>, <xref ref-type="bibr" rid="alpers.REF.horvath.2008.558">Horvath et al 2008</xref>].</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="alpers.Genetic_Counseling">
        <title>Genetic Counseling</title>
        <sec id="alpers.Mode_of_Inheritance">
          <title>Mode of Inheritance</title>
          <p>The <italic toggle="yes">POLG</italic>-related disorders in the spectrum of AHS, MCHS, (including SCAE), ANS (including MIRAS and SANDO), and autosomal recessive progressive external ophthalmoplegia (arPEO) are inherited in an autosomal recessive manner.</p>
          <p>Autosomal dominant progressive external ophthalmoplegia (CPEO+) is inherited in an autosomal dominant manner with reduced penetrance.</p>
        </sec>
        <sec id="alpers.Risk_to_Family_Members__Autosomal">
          <title>Risk to Family Members &#x02014; Autosomal Recessive Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>In general, the parents of an affected child are obligate heterozygotes and therefore carry one <italic toggle="yes">POLG</italic> pathogenic variant.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are generally believed to be asymptomatic. However, some individuals with a heterozygous <italic toggle="yes">POLG</italic> pathogenic variant are reported to have manifestations of <italic toggle="yes">POLG</italic>-related disorders. Because knowledge of these disorders is changing quickly individuals who are heterozygous should be reevaluated by history and physical examination every few years for symptoms and signs of <italic toggle="yes">POLG</italic>-related disorders.</p>
            </list-item>
          </list>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>At conception, the sibs of an individual with an autosomal recessive <italic toggle="yes">POLG</italic>-related disorder have a 25% chance of being affected, a 50% chance of being a carrier, and a 25% chance of being unaffected and not a carrier.</p>
            </list-item>
            <list-item>
              <p>Once an at-risk sib is known to be unaffected, the risk of his/her being a carrier is 2/3.</p>
            </list-item>
            <list-item>
              <p>Heterozygotes (carriers) are generally asymptomatic (see discussion in <xref ref-type="sec" rid="alpers.Risk_to_Family_Members__Autosomal">Risk to Family Members&#x02014;Autosomal Recessive Inheritance</xref>, <bold>Parents of a proband</bold>).</p>
            </list-item>
          </list>
          <p>
            <bold>Offspring of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Individuals with some <italic toggle="yes">POLG</italic>-related disorders (e.g., Alpers-Huttenlocher syndrome) do not reproduce.</p>
            </list-item>
            <list-item>
              <p>The offspring of individuals with less severe manifestations of a <italic toggle="yes">POLG</italic>-related disorder will be obligate heterozygotes for a <italic toggle="yes">POLG</italic> pathogenic variant.</p>
            </list-item>
          </list>
          <p><bold>Other family members.</bold> Each sib of the proband&#x02019;s parents is at a 50% risk of being a carrier of a <italic toggle="yes">POLG</italic> pathogenic variant.</p>
        </sec>
        <sec id="alpers.Carrier_Detection">
          <title>Carrier Detection</title>
          <p>Carrier testing for at-risk relatives requires prior identification of the <italic toggle="yes">POLG</italic> pathogenic variants in the family.</p>
          <p>Individuals from populations with a high carrier rate for <italic toggle="yes">POLG</italic> pathogenic variants and/or a high rate of consanguinity should be offered genetic counseling and carrier testing.</p>
        </sec>
        <sec id="alpers.Risk_to_Family_Members__Autosomal_1">
          <title>Risk to Family Members &#x02014; Autosomal Dominant Inheritance</title>
          <p>
            <bold>Parents of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Most individuals diagnosed with an autosomal dominant <italic toggle="yes">POLG</italic>-related disorder have an affected parent.</p>
            </list-item>
            <list-item>
              <p>A proband with an autosomal dominant <italic toggle="yes">POLG</italic>-related disorder may have the disorder as the result of a new pathogenic variant. The proportion of cases caused by <italic toggle="yes">de novo</italic> pathogenic variants is thought to be low (&#x0003c;1%); however, because simplex cases (i.e., a single occurrence in a family) have not been evaluated sufficiently to determine whether the pathogenic variant was <italic toggle="yes">de novo</italic>, the proportion of cases caused by <italic toggle="yes">de novo</italic> variants is unknown.</p>
            </list-item>
            <list-item>
              <p>If the pathogenic variant found in the proband cannot be detected in the DNA of either parent, two possible explanations are germline mosaicism in a parent or a <italic toggle="yes">de novo</italic> pathogenic variant in the proband.</p>
            </list-item>
            <list-item>
              <p>Evaluation of parents may determine that one is affected but has escaped previous diagnosis because of a milder phenotypic presentation. Therefore, an apparently negative family history cannot be confirmed until appropriate evaluations have been performed.</p>
            </list-item>
            <list-item>
              <p>Recommendations for the evaluation of parents of a proband with an apparent <italic toggle="yes">de novo</italic> pathogenic variant include performing a complete history and physical examination, focusing on the most common symptoms and/or clinical features of <italic toggle="yes">POLG</italic>-related disease (ophthalmoplegia, weakness, ataxia, and neuropathy). Because migraine, depression, gastrointestinal problems, and seizures are so common in the general population, their presence as isolated findings is not likely to be relevant. If there is an ophthalmoplegia, or a constellation of features suggestive of <italic toggle="yes">POLG</italic>-related disease, molecular genetic testing can be performed to confirm the diagnosis.</p>
            </list-item>
          </list>
          <p>Note: (1) Although most individuals diagnosed with an autosomal dominant <italic toggle="yes">POLG</italic>-related disorder have an affected biological parent, the family history may appear to be negative because of failure to recognize the disorder in family members, early death of the parent before the onset of symptoms, or late onset of the disease in the affected parent. (2) If the parent is the individual in whom the pathogenic variant first occurred s/he may have somatic mosaicism for the pathogenic variant and may be mildly/minimally affected.</p>
          <p>
            <bold>Sibs of a proband</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The risk to the sibs of the proband depends on the genetic status of the proband&#x02019;s parents.</p>
            </list-item>
            <list-item>
              <p>If a parent of the proband is affected, the risk to the sibs is 50%.</p>
            </list-item>
            <list-item>
              <p>When the parents are clinically unaffected, the risk to the sibs of a proband appears to be low.</p>
            </list-item>
            <list-item>
              <p>The sibs of a proband with clinically unaffected parents are still at increased risk (for the disorder) because of the possibility of reduced penetrance in a parent.</p>
            </list-item>
            <list-item>
              <p>If the <italic toggle="yes">POLG</italic> pathogenic variant found in the proband cannot be detected in the DNA of either parent, the risk to sibs is low, but greater than that of the general population because of the possibility of germline mosaicism.</p>
            </list-item>
          </list>
          <p><bold>Offspring of a proband.</bold> Each child of an individual with an autosomal dominant <italic toggle="yes">POLG</italic>-related disorder has a 50% chance of inheriting the pathogenic variant.</p>
          <p><bold>Other family members of a proband.</bold> The risk to other family members depends on the status of the proband's parents: if a parent is affected or has a pathogenic variant, his or her family members may be at risk.</p>
        </sec>
        <sec id="alpers.Related_Genetic_Counseling_Issues">
          <title>Related Genetic Counseling Issues</title>
          <p>
            <bold>At-risk family members</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>Sibs who are similar in age or younger than the proband may still be at risk and in need of diagnostic evaluation.</p>
            </list-item>
            <list-item>
              <p>Older unaffected sibs (as well as other family members) may have only a single pathogenic variant, but need to be informed that (1) some heterozygotes have had symptoms at a later age possibly related to their carrier status, and (2) heterozygotes (i.e., those with a single pathogenic allele) are at increased risk of having a child with the disorder, particularly if their reproductive partner is of an ethnic group with high carrier frequency.</p>
            </list-item>
          </list>
          <p>
            <bold>Family planning</bold>
          </p>
          <list list-type="bullet">
            <list-item>
              <p>The optimal time for determination of genetic risk, clarification of carrier status, and discussion of the availability of prenatal testing is before pregnancy.</p>
            </list-item>
            <list-item>
              <p>It is appropriate to offer genetic counseling (including discussion of potential risks to offspring and reproductive options) to young adults who are affected, are carriers, or are at risk of being carriers.</p>
            </list-item>
          </list>
          <p><bold>DNA banking</bold> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of affected individuals.</p>
        </sec>
        <sec id="alpers.Prenatal_Testing_and_Preimplantat">
          <title>Prenatal Testing and Preimplantation Genetic Diagnosis</title>
          <p>Once the <italic toggle="yes">POLG</italic> pathogenic variant(s) have been identified in an affected family member, prenatal testing for a pregnancy at increased risk and preimplantation genetic diagnosis for adPEO are possible.</p>
          <p>Requests for prenatal testing for adult-onset conditions such as adPEO are not common. Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. Although most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p>
        </sec>
      </sec>
      <sec id="alpers.Resources">
        <title>Resources</title>
      </sec>
      <sec id="alpers.Molecular_Genetics">
        <title>Molecular Genetics</title>
        <sec id="alpers.Molecular_Genetic_Pathogenesis">
          <title>Molecular Genetic Pathogenesis</title>
          <p>The mitochondrion comprises almost 1500 proteins, but only the 13 that comprise small portions of the respiratory chain complexes I, III, IV, and V are encoded by the mitochondrial genome. The terminal portion of energy production occurs in the respiratory chain; disruption of the production and/or assembly of any component leads to a deficiency of ATP and resultant cellular energy failure. Unlike nuclear DNA, which replicates with each cell division, mtDNA replicates continuously and independently of cell division. This task specifically requires polymerase gamma, the only DNA polymerase in humans that allows for replication and repair of mtDNA.</p>
          <p><italic toggle="yes">POLG</italic> encodes DNA polymerase gamma (pol gamma), the enzyme required for mitochondrial DNA synthesis. The three functional domains of pol gamma:</p>
          <list list-type="bullet">
            <list-item>
              <p>Polymerase, responsible for replication</p>
            </list-item>
            <list-item>
              <p>Exonuclease, responsible for proofreading</p>
            </list-item>
            <list-item>
              <p>Linker, the region between the other two domains</p>
            </list-item>
          </list>
          <p>Reports suggest that pathogenic variants in each of these three regions of <italic toggle="yes">POLG</italic> have rather distinct clinical consequences (see <xref ref-type="sec" rid="alpers.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</xref>).</p>
          <p>Mitochondrial DNA replication requires a heterotrimer of one 140-kd catalytic subunit of pol gamma and two accessory 55-kd subunits encoded by <italic toggle="yes">POLG2</italic> (located at chromosome 17q23-24) that assist in binding and processing the synthesized DNA. The twinkle protein, encoded by <italic toggle="yes">TWNK</italic>, serves the important function of a 5'&#x02192;3' DNA helicase.</p>
          <p>The first pathogenic variants in <italic toggle="yes">POLG</italic> were identified in families with autosomal dominant chronic progressive external ophthalmoplegia [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al 2001</xref>] followed by reports of <italic toggle="yes">POLG</italic> pathogenic variants associated with SANDO and ataxia-neuropathy conditions [<xref ref-type="bibr" rid="alpers.REF.van_goethem.2003b.133">Van Goethem et al 2003b</xref>, <xref ref-type="bibr" rid="alpers.REF.van_goethem.2004.1251">Van Goethem et al 2004</xref>]. The first link between a mtDNA depletion disorder and a <italic toggle="yes">POLG</italic> pathogenic variant was made by <xref ref-type="bibr" rid="alpers.REF.naviaux.2004.706">Naviaux &#x00026; Nguyen [2004]</xref> in two probands diagnosed with Alpers-Huttenlocher syndrome (AHS).</p>
          <p><bold>Gene structure.</bold>
<italic toggle="yes">POLG</italic> comprises 23 exons and is 18,476 bases in length. See <related-object source-id="gene" document-id="alpers" object-id="alpers.molgen.TA">Table A</related-object> for a detailed summary of gene and protein information.</p>
          <p><bold>Benign variants.</bold> A number of <italic toggle="yes">POLG</italic> pathogenic variants have been found to occur in <italic toggle="yes">cis</italic> configuration with the benign variant p.Glu1143Gly. Heterozygosity for this haplotype does not cause mitochondrial disease, with the exception of a single report of a person having ataxia, PEO, and parkinsonism [<xref ref-type="bibr" rid="alpers.REF.luoma.2005.1907">Luoma et al 2005</xref>, <xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>]. The p.Glu1143Gly variant occurs in 3%-4% of the healthy population; individuals homozygous for p.Glu1143Gly are reported to be healthy (see <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">Table 5</xref>). However, the p.Glu1143Gly normal variant does modulate the deleterious effects of the p.Trp748Ser disease-causing allele by partially rescuing activity (increasing DNA binding affinity and polymerase activity) but decreasing protein stability [<xref ref-type="bibr" rid="alpers.REF.chan.2006.3473">Chan et al 2006</xref>]. This same variant may increase the liver&#x02019;s sensitivity to valproic acid exposure [<xref ref-type="bibr" rid="alpers.REF.stewart.2010.1791">Stewart et al 2010</xref>]. As with p.Glu1143Gly, the presence of p.Gln1236His can induce liver sensitivity to valproic acid exposure. It is estimated that the presence of either the p.Glu1143Gly or p.Gln1236His variant increases valproic acid sensitivity more than 20-fold [<xref ref-type="bibr" rid="alpers.REF.stewart.2010.1791">Stewart et al 2010</xref>]. Six patients reported previously with AHS and liver failure did not have either variant [Wong, personal communication]. Rare reports describe long-term use of valproic acid exposure with <italic toggle="yes">POLG</italic> pathogenic variant(s) without liver failure [<xref ref-type="bibr" rid="alpers.REF.tzoulis.2006.1685">Tzoulis et al 2006</xref>].</p>
          <p>The p.Gly517Val variant, a common SNP that was initially reported to be associated with various POLG phenotypes including autosomal dominant and recessive ataxia, neuropathy, myopathy and microcephaly, progressive external ophthalmoplegia, diabetes, strokes, hypotonia, and epilepsy, has been shown to have normal (80%-90%) pol gamma activity and should not be considered a pathogenic variant [<xref ref-type="bibr" rid="alpers.REF.kasiviswanathan.2011.929">Kasiviswanathan &#x00026; Copeland 2011</xref>].</p>
          <p>Because many of the reported pathogenic variants come from singleton cases without supporting data, it is important to gain a better understanding of which variants may not ultimately be found to be pathogenic. The use of mouse models, <italic toggle="yes">S. cerevisiae</italic>, and the 3D-structure of the human pol gamma will help gain a better understanding over time [<xref ref-type="bibr" rid="alpers.REF.stumpf.2011.219">Stumpf &#x00026; Copeland 2011</xref>].</p>
          <p><bold>Pathogenic variants.</bold> Pathogenic variants are found throughout the gene. Almost 200 variants in <italic toggle="yes">POLG</italic> are reported to cause disease. Of these, more than 75 are associated with AHS.</p>
          <p>Both the p.Ala467Thr and the p.Trp748Ser pathogenic variants are located in the linker region of the gene.</p>
          <list list-type="bullet">
            <list-item>
              <p>The most common AHS-causing <italic toggle="yes">POLG</italic> pathogenic variant is p.Ala467Thr, located near the exonuclease domain in the early linker region of pol gamma.</p>
            </list-item>
            <list-item>
              <p>The second most common <italic toggle="yes">POLG</italic> pathogenic variant is p.Trp748Ser, which causes AHS, the ataxia-neuropathy spectrum disorders, and PEO.</p>
            </list-item>
          </list>
          <table-wrap id="alpers.T.frequency_of_the_most_common_po" orientation="portrait" position="anchor">
            <label>Table 4. </label>
            <caption>
              <p>Frequency of the Most Common <italic toggle="yes">POLG</italic> Pathogenic Variants</p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">POLG</italic> Pathogenic Variant</th>
                  <th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Prevalence</th>
                  <th id="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" rowspan="4" valign="middle" align="left" scope="row" colspan="1">p.Ala467Thr</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.6% Belgian</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.van_goethem.2001.211">Van Goethem et al [2001]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">0.17%-0.69% European</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.horvath.2006.1674">Horvath et al [2006]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">0.69% UK</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.craig.2007.e69">Craig et al [2007]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">0% Italian</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.craig.2007.e69">Craig et al [2007]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" rowspan="2" valign="middle" align="left" scope="row" colspan="1">p.Trp748Ser</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.8% Finland</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.hakonen.2005.430">Hakonen et al [2005]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">0% Italian</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">
                    <xref ref-type="bibr" rid="alpers.REF.craig.2007.e69">Craig et al [2007]</xref>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.Gly848Ser</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.05%-0.1%</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_1" valign="middle" align="left" scope="row" rowspan="1" colspan="1">p.[Thr251Ile]+[Pro587Leu]&#x000a0;<sup>1</sup></td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">0.05%</td>
                  <td headers="hd_h_alpers.T.frequency_of_the_most_common_po_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1"/>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn id="alpers.TF.4.1">
                <label>1. </label>
                <p>Indicates a different pathogenic variant on each of two alleles (see <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://varnomen.hgvs.org">varnomen.hgvs.org</ext-link>).</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p>An up-to-date listing of all pathogenic variants is available at <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://tools.niehs.nih.gov/polg/index.cfm">tools.niehs.nih.gov</ext-link>, managed by William Copeland, PhD.</p>
          <table-wrap id="alpers.T.polg_variants_discussed_in_this" orientation="portrait" position="anchor">
            <label>Table 5. </label>
            <caption>
              <p><italic toggle="yes">POLG</italic> Variants Discussed in This <italic toggle="yes">GeneReview</italic></p>
            </caption>
            <table frame="hsides" rules="groups">
              <thead>
                <tr>
                  <th id="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_1" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Variant Classification</th>
                  <th id="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" align="left" scope="col" rowspan="1" colspan="1">DNA Nucleotide Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Predicted Protein Change<break/>(Alias&#x000a0;<sup>1</sup>)</th>
                  <th id="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_4" valign="middle" align="left" scope="col" rowspan="1" colspan="1">Reference Sequences</th>
                </tr>
              </thead>
              <tbody>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_1" rowspan="10" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Benign</bold>
                  </td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.52T&#x0003e;G</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro18Ser</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_4" rowspan="19" valign="middle" align="left" colspan="1">
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/nucleotide/187171275">NM_002693.2</ext-link>
                    <break/>
                    <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/protein/4505937">NP_002684.1</ext-link>
                  </td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.578G&#x0003e;A</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg193Gln</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.970T&#x0003e;G</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro324Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1550G&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly517Val</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1636C&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg546Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1984C&#x0003e;A</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu662Lys</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3424C&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1142Trp</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3428A&#x0003e;G</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Glu1143Gly&#x000a0;<sup>2</sup></td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3436C&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg1146Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3708G&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gln1236His</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_1" rowspan="9" valign="middle" align="left" scope="row" colspan="1">
                    <bold>Pathogenic</bold>
                  </td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" align="left" rowspan="1" colspan="1">c.695G&#x0003e;A</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Arg232His</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.752C&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Thr251Ile</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1399G&#x0003e;A</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Ala467Thr</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.1760C&#x0003e;T</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Pro587Leu</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2243G&#x0003e;C</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Trp748Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2542G&#x0003e;A</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly848Ser</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.2864A&#x0003e;G</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Tyr955Cys</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3488T&#x0003e;G</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Met1163Arg</td>
                </tr>
                <tr>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_2" valign="middle" colspan="1" align="left" scope="row" rowspan="1">c.3630dupC<break/>(3630insC)</td>
                  <td headers="hd_h_alpers.T.polg_variants_discussed_in_this_1_1_1_3" valign="middle" align="left" rowspan="1" colspan="1">p.Gly1211ArgfsTer6<break/>(Tyr1210fs1216Ter)</td>
                </tr>
              </tbody>
            </table>
            <table-wrap-foot>
              <fn>
                <p>Note on variant classification: Variants listed in the table have been provided by the authors. <italic toggle="yes">GeneReviews</italic> staff have not independently verified the classification of variants.</p>
              </fn>
              <fn>
                <p>Note on nomenclature: <italic toggle="yes">GeneReviews</italic> follows the standard naming conventions of the Human Genome Variation Society (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://varnomen.hgvs.org/">varnomen.hgvs.org</ext-link>). See <related-object link-type="booklink" source-id="gene" document-id="app3" document-type="appendix">Quick Reference</related-object> for an explanation of nomenclature.</p>
              </fn>
              <fn id="alpers.TF.5.1">
                <label>1. </label>
                <p>Variant designation that does not conform to current naming conventions</p>
              </fn>
              <fn id="alpers.TF.5.2">
                <label>2. </label>
                <p>Modulates activity of the p.Trp748Ser disease-causing allele (see <bold>Benign variants</bold>)</p>
              </fn>
            </table-wrap-foot>
          </table-wrap>
          <p><bold>Normal gene product.</bold>
<italic toggle="yes">POLG</italic> encodes DNA polymerase gamma (pol gamma), which comprises 1239 amino acids with a molecular weight of 139 kd; pol gamma is an enzyme required for mitochondrial DNA synthesis with two functional domains and one linker domain (see <xref ref-type="sec" rid="alpers.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>).</p>
          <p><bold>Abnormal gene product.</bold> See <xref ref-type="sec" rid="alpers.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>.</p>
          <p>The clinical features of the diseases caused by mutation of <italic toggle="yes">POLG</italic> most likely result from depletion over time of normal mtDNA, with resultant reduced enzymatic activity of the electron transport chain components necessary for oxidative phosphorylation. The POLG gene product is arranged such that the 3&#x02019;-5&#x02019; exonuclease activity is found in the first third of the protein and the DNA polymerase active site is found in the last third of the protein. These two active sites are separated by a linker region that contacts the POLG2 accessory subunit. The adPEO-causing pathogenic variants are the only pathogenic variants that are clustered; they are found, for the most part, in the active site region of the DNA polymerase.</p>
          <p>The effect of several pathogenic variants on the function of the gene product has been studied.</p>
          <list list-type="bullet">
            <list-item>
              <p>The effect of the p.Ala467Thr substitution is a severe reduction in DNA polymerase gamma activity (4% of wildtype pol gamma activity) as a consequence of reduced affinity for dNTPs and lower catalysis [<xref ref-type="bibr" rid="alpers.REF.chan.2005.31341">Chan et al 2005</xref>]. In addition, the p.Ala467Thr enzyme is defective in functional association with the POLG2 accessory subunit which is critical for highly processive DNA synthesis (defined as the number of nucleotides incorporated per DNA binding event). The combined defects lead to stalling at the replication fork and depletion of mtDNA over time.</p>
            </list-item>
            <list-item>
              <p>The p.Trp748Ser pathogenic variant results in low DNA polymerase activity, low processivity, and a severe DNA-binding defect, but interactions with the POLG2 accessory subunit are normal [<xref ref-type="bibr" rid="alpers.REF.chan.2006.3473">Chan et al 2006</xref>]. The phenotypic effects of p.Trp748Ser are modulated when in <italic toggle="yes">cis</italic> with a normal variant (see <xref ref-type="sec" rid="alpers.Molecular_Genetic_Pathogenesis">Molecular Genetic Pathogenesis</xref>, <bold>Benign variants</bold>). AHS results when the p.[Trp748Ser;p.Glu1143Gly] haplotype occurs in <italic toggle="yes">trans</italic> configuration with a different pathogenic variant on the other allele, e.g., p.Arg232His (see <xref ref-type="table" rid="alpers.T.polg_variants_discussed_in_this">Table 5</xref>).</p>
            </list-item>
            <list-item>
              <p>The p.Tyr955Cys pathogenic variant, although rare, is the most observed <italic toggle="yes">POLG</italic> pathogenic variant in individuals with adPEO and causes a severe reduction in DNA polymerase activity (&#x0003c;1% of wildtype POLG activity) [<xref ref-type="bibr" rid="alpers.REF.graziewicz.2004.770">Graziewicz et al 2004</xref>]. This pathogenic variant also results in a mutator polymerase, causing a ten- to 100-fold increase in nucleotide mis-insertion errors, most likely as a consequence of a 45-fold decrease in binding affinity for the incoming nucleoside triphosphates [<xref ref-type="bibr" rid="alpers.REF.ponamarev.2002.15225">Ponamarev et al 2002</xref>].</p>
            </list-item>
          </list>
        </sec>
      </sec>
      <sec id="alpers.References">
        <title>References</title>
        <sec id="alpers.Literature_Cited">
          <title>Literature Cited</title>
          <ref-list id="alpers.Literature_Cited.reflist0">
            <ref id="alpers.REF.amatibonneau.2008.338">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Amati-Bonneau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Valentino</surname>
                    <given-names>ML</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gallardo</surname>
                    <given-names>ME</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bornstein</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Boissi&#x000e8;re</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Campos</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rivera</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de la Aleja</surname>
                    <given-names>JG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carroccia</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iommarini</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labauge</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Figarella-Branger</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marcorelles</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furby</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beauvais</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Letournel</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liguori</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>La Morgia</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Montagna</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Liguori</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zanna</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rugolo</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cossarizza</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wissinger</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Verny</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwarzenbacher</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mart&#x000ed;n</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arenas</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ayuso</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garesse</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lenaers</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonneau</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carelli</surname>
                    <given-names>V</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>OPA1 mutations induce mitochondrial DNA instability and optic atrophy 'plus' phenotypes.</article-title>
                <source>Brain.</source>
                <volume>131</volume>
                <fpage>338</fpage>
                <lpage>51</lpage>
                <pub-id pub-id-type="pmid">18158317</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.bekheirnia.2012.209">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bekheirnia</surname>
                    <given-names>MR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eble</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Willis</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaibani</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dhar</surname>
                    <given-names>SU</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>POLG mutation in a patient with cataracts, early-onset distal muscle weakness and atrophy, ovarian dysgenesis and 3-methylglutaconic aciduria.</article-title>
                <source>Gene</source>
                <volume>499</volume>
                <fpage>209</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">22405928</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.bicknese.1992.767">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bicknese</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>May</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hickey</surname>
                    <given-names>WF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dodson</surname>
                    <given-names>WE</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Early childhood hepatocerebral degeneration misdiagnosed as valproate hepatotoxicity.</article-title>
                <source>Ann Neurol</source>
                <volume>32</volume>
                <fpage>767</fpage>
                <lpage>75</lpage>
                <pub-id pub-id-type="pmid">1471867</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.bonnen.2013.471">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bonnen</surname>
                    <given-names>PE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yarham</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Besse</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Faqeih</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Asmari</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saleh</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eyaid</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hadeel</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yau</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simcox</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miwa</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donti</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abu-Amero</surname>
                    <given-names>KK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graham</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scott</surname>
                    <given-names>KL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in FBXL4 cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>93</volume>
                <fpage>471</fpage>
                <lpage>81</lpage>
                <pub-id pub-id-type="pmid">23993193</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.bourdon.2007.776">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Bourdon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minai</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Serre</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jais</surname>
                    <given-names>JP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aubert</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chr&#x000e9;tien</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paquis-Flucklinger</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arakawa</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nakamura</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mutation of RRM2B, encoding p53-controlled ribonucleotide reductase (p53R2), causes severe mitochondrial DNA depletion.</article-title>
                <source>Nat Genet.</source>
                <volume>39</volume>
                <fpage>776</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">17486094</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.boyd.1986.75">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Boyd</surname>
                    <given-names>SG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harden</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Egger</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pampiglione</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1986</year>
                <article-title>Progressive neuronal degeneration of childhood with liver disease ("Alpers' disease"): characteristic neurophysiological features.</article-title>
                <source>Neuropediatrics.</source>
                <volume>17</volume>
                <fpage>75</fpage>
                <lpage>80</lpage>
                <pub-id pub-id-type="pmid">3724991</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.chan.2006.3473">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Modulation of the W748S mutation in DNA polymerase gamma by the E1143G polymorphismin mitochondrial disorders.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>15</volume>
                <fpage>3473</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">17088268</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.chan.2005.31341">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>SSL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>The common A467T mutation in the human mitochondrial DNA polymerase (POLG) compromises catalytic efficiency and interaction with the accessory subunit.</article-title>
                <source>J Biol Chem</source>
                <volume>280</volume>
                <fpage>31341</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">16024923</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.christopher.2013.1136">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Christopher</surname>
                    <given-names>AC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koshy</surname>
                    <given-names>K</given-names>
                  </name>
                </person-group>
                <article-title>Neurological picture. Periventricular heterotopia in refractory epilepsy.</article-title>
                <source>J Neurol Neurosurg Psychiatry.</source>
                <year>2013</year>
                <volume>84</volume>
                <fpage>1136</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">23715917</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.compton.2011.104">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Compton</surname>
                    <given-names>AG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Troedson</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Procopis</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brundage</surname>
                    <given-names>EK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yamazaki</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>Application of oligonucleotide array CGH in the detection of a large intragenic deletion in POLG associated with Alpers Syndrome.</article-title>
                <source>Mitochondrion</source>
                <volume>11</volume>
                <fpage>104</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">20708716</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.craig.2007.e69">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Craig</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiangyou</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gellera</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>The A467T and W748S POLG substitutions are a rare cause of adult-onset ataxia in Europe.</article-title>
                <source>Brain.</source>
                <volume>130</volume>
                <fpage>E69</fpage>
                <pub-id pub-id-type="pmid">17438011</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.darin.2001.377">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Darin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldfors</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moslemi</surname>
                    <given-names>AR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tulinius</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The incidence of mitochondrial encephalomyopathies in childhood: clinical features and morphological, biochemical, and DNA anbormalities.</article-title>
                <source>Ann Neurol.</source>
                <volume>49</volume>
                <fpage>377</fpage>
                <lpage>83</lpage>
                <pub-id pub-id-type="pmid">11261513</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.davidzon.2006.859">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davidzon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Greene</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klos</surname>
                    <given-names>KJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahlskog</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Early-onset familial parkinsonism due to POLG mutations.</article-title>
                <source>Ann Neurol.</source>
                <volume>59</volume>
                <fpage>859</fpage>
                <lpage>62</lpage>
                <pub-id pub-id-type="pmid">16634032</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.davidzon.2005.921">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Davidzon</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferraris</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinzii</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peters</surname>
                    <given-names>HL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kirby</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>POLG mutations and Alpers syndrome.</article-title>
                <source>Ann Neurol.</source>
                <volume>57</volume>
                <fpage>921</fpage>
                <lpage>3</lpage>
                <pub-id pub-id-type="pmid">15929042</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.de_vries.2008.s299">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>de Vries</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodenburg</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morava</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lammens</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Heuvel</surname>
                    <given-names>LP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Korenke</surname>
                    <given-names>GC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Smeitink</surname>
                    <given-names>JA</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Normal biochemical analysis of the oxidative phosphorylation (OXPHOS) system in a child with POLG mutations: a cautionary note.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>31</volume>
                <supplement>Suppl 2</supplement>
                <fpage>S299</fpage>
                <lpage>302</lpage>
                <pub-id pub-id-type="pmid">18500570</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.di_fonzo.2003.498">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Di Fonzo</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Crimi</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sara</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Del Bo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bresolin</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>POLG mutations in sporadic mitochondrial disorders with multiple mtDNA deletions.</article-title>
                <source>Hum Mutat.</source>
                <volume>22</volume>
                <fpage>498</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">14635118</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.dimmock.2008.330">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Dimmock</surname>
                    <given-names>DP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dionisi-Vici</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrozzo</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shieh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>LY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Truong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sifry-Platt</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lucioli</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santorelli</surname>
                    <given-names>FM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ficicioglu</surname>
                    <given-names>CH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wierenga</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Enns</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lipson</surname>
                    <given-names>MH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vallance</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Craigen</surname>
                    <given-names>WJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scaglia</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Clinical and molecular features of mitochondrial DNA depletion due to mutations in deoxyguanosine kinase.</article-title>
                <source>Hum Mutat.</source>
                <volume>29</volume>
                <fpage>330</fpage>
                <lpage>1</lpage>
                <pub-id pub-id-type="pmid">18205204</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.elpeleg.2005.1081">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Miller</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hershkovitz</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bondi-Rubinstein</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagnamenta</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eshhar</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Deficiency of the ADP-forming succinyl-CoA synthase activity is associated with encephalomyopathy and mitochondrial DNA depletion.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>76</volume>
                <fpage>1081</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15877282</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.fadic.1997.239">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Fadic</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Russell</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vedanarayanan</surname>
                    <given-names>VV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lehar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kuncl</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johns</surname>
                    <given-names>DR</given-names>
                  </name>
                </person-group>
                <year>1997</year>
                <article-title>Sensory ataxic neuropathy as the presenting feature of a novel mitochondrial disease.</article-title>
                <source>Neurology</source>
                <volume>49</volume>
                <fpage>239</fpage>
                <lpage>45</lpage>
                <pub-id pub-id-type="pmid">9222196</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.ferrari.2005.723">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filosto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Briem</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Simonati</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Infantile hepatocerebral syndromes associated with mutations in the mitochondrial DNA polymerase-gammaA.</article-title>
                <source>Brain.</source>
                <volume>128</volume>
                <fpage>723</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15689359</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.filosto.2003.1279">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Filosto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nishigaki</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pancrudo</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Harati</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gooch</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mankodi</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bayne</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonilla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shanske</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2003</year>
                <article-title>Clinical and genetic heterogeneity in progressive external ophthalmoplegia due to mutations in polymerase gamma.</article-title>
                <source>Arch Neurol.</source>
                <volume>60</volume>
                <fpage>1279</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">12975295</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.gai.2013.482">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gai</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ghezzi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnson</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biagosch</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shamseldin</surname>
                    <given-names>HE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reyes</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tsukikawa</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sheldon</surname>
                    <given-names>CA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Srinivasan</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorza</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kremer</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Polyak</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Place</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Consugar</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ostrovsky</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vidoni</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Robinson</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sondheimer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salih</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al-Jishi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Raab</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bean</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Furlan</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamperti</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Konstantopoulou</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Huemer</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pierce</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sperl</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alkuraya</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Mutations in FBXL4, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy.</article-title>
                <source>Am J Hum Genet.</source>
                <year>2013</year>
                <volume>93</volume>
                <fpage>482</fpage>
                <lpage>95</lpage>
                <pub-id pub-id-type="pmid">23993194</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.gallagher.2009.550">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gallagher</surname>
                    <given-names>RC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Hove</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scharer</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hyland</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Plecko</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mercimek-Mahmutoglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stockler-Ipsiroglu</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salomons</surname>
                    <given-names>GS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>EH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Struys</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jakobs</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Folinic acid-responsive seizures are identical to pyridoxine-dependent epilepsy.</article-title>
                <source>Ann Neurol</source>
                <volume>65</volume>
                <fpage>550</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">19142996</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.gauthiervillars.2001.150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gauthier-Villars</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Landrieu</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacquemin</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chretien</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rotig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rustin</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Respiratory chain deficiency in Alpers syndrome.</article-title>
                <source>Neuropediatrics</source>
                <volume>32</volume>
                <fpage>150</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">11521212</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.gold.2001.309">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Gold</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>BH</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Treatment of mitochondrial cytopathies.</article-title>
                <source>Semin Neurol.</source>
                <volume>21</volume>
                <fpage>309</fpage>
                <lpage>25</lpage>
                <pub-id pub-id-type="pmid">11641821</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.graziewicz.2004.770">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Graziewicz</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bienstock</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Structure-function defects of human mitochondrial DNA polymerase in autosomal dominant progressive external ophthalmoplegia.</article-title>
                <source>Nat Struct Mol Biol</source>
                <volume>11</volume>
                <fpage>770</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">15258572</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hakonen.2005.430">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hakonen</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Heiskanen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juvonen</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lappalainen</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luoma</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rantamaki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Goethem</surname>
                    <given-names>GV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lofgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hackman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Paetau</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaakkola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majamaa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Varilo</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaariainen</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindoff</surname>
                    <given-names>LA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Mitochondrial DNA polymerase W748S mutation: a common cause of autosomal recessive ataxia with ancient European origin.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>77</volume>
                <fpage>430</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">16080118</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hanisch.2014">
              <mixed-citation publication-type="other">Hanisch F, Kornhuber M, Alston CL, Taylor RW, Deschauer M, Zierz S. SANDO syndrome in a cohort of 107 patients with CPEO and mitochondrial DNA deletions. J Neurol Neurosurg Psychiatry. 2014 Aug 20. pii: jnnp-2013-306748.</mixed-citation>
            </ref>
            <ref id="alpers.REF.harrower.2008.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Harrower</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houlden</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Warner</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>O'Donovan</surname>
                    <given-names>DG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Findlay</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Silva</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>POLG1 mutations manifesting as autosomal recessive axonal Charcot-Marie-Tooth disease.</article-title>
                <source>Arch Neurol</source>
                <volume>65</volume>
                <fpage>133</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">18195151</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hasselmann.2010.58">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hasselmann</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blau</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramaekers</surname>
                    <given-names>VT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quadros</surname>
                    <given-names>EV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sequeira</surname>
                    <given-names>JM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weissert</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <article-title>Cerebral folate deficiency and CNS inflammatory markers in Alpers disease.</article-title>
                <source>Mol Genet Metab.</source>
                <year>2010</year>
                <volume>99</volume>
                <fpage>58</fpage>
                <lpage>61</lpage>
                <pub-id pub-id-type="pmid">19766516</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.heidari.2008.489">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Heidari</surname>
                    <given-names>MM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Houshmand</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hosseinkhani</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nafissi</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scheiber-Mojdehkar</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Khatami</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Association between trinucleotide CAG repeats of the DNA polymerase gene (POLG) with age of onset of Iranian Friedreich's ataxia patients.</article-title>
                <source>Neurol Sci</source>
                <volume>29</volume>
                <fpage>489</fpage>
                <lpage>93</lpage>
                <pub-id pub-id-type="pmid">19043662</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hirano.2001.2163">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>ANT1, Twinkle, POLG, and TP: New genes open our eyes to ophthalmoplegia.</article-title>
                <source>Neurology</source>
                <volume>57</volume>
                <fpage>2163</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">11756592</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.horvath.2008.558">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gorman</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>How can we treat mitochondrial encephalomyopathies? Approaces to treatment.</article-title>
                <source>Neurotherapeutics</source>
                <volume>5</volume>
                <fpage>558</fpage>
                <lpage>68</lpage>
                <pub-id pub-id-type="pmid">19019307</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.horvath.2006.1674">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>F&#x000fc;tterer</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lochm&#x000fc;ller</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ramesh</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopstock</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freisinger</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Salvi</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mayr</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santer</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tesarova</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeman</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hanna</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fialho</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Phenotypic spectrum associated with mutations of the mitochondrial polymerase &#x003b3; gene.</article-title>
                <source>Brain.</source>
                <volume>129</volume>
                <fpage>1674</fpage>
                <lpage>84</lpage>
                <pub-id pub-id-type="pmid">16621917</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hudson.2008.329">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Amati-Bonneau</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Blakely</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schaefer</surname>
                    <given-names>AM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Griffiths</surname>
                    <given-names>PG</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahlqvist</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Reynier</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McFarland</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Mutation of OPA1 causes dominant optic atrophy with external ophthalmoplegia, ataxia, deafness and multiple mitochondrial DNA deletions: a novel disorder of mtDNA maintenance.</article-title>
                <source>Brain.</source>
                <volume>131</volume>
                <fpage>329</fpage>
                <lpage>37</lpage>
                <pub-id pub-id-type="pmid">18065439</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.hudson.2006.r244">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mitochondrial DNA polymerase-gamma and human disease</article-title>
                <source>Hum Mol Genet.</source>
                <volume>15</volume>
                <fpage>R244</fpage>
                <lpage>52</lpage>
                <pub-id pub-id-type="pmid">16987890</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.huttenlocher.1976.186">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Huttenlocher</surname>
                    <given-names>PR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Solitare</surname>
                    <given-names>GB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Adams</surname>
                    <given-names>G</given-names>
                  </name>
                </person-group>
                <year>1976</year>
                <article-title>Infantile diffuse cerebral degeneration with hepatic cirrhosis</article-title>
                <source>Arch Neurol</source>
                <volume>33</volume>
                <fpage>186</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">1252162</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.karadimas.2006.544">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Karadimas</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vu</surname>
                    <given-names>TH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holve</surname>
                    <given-names>SA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chronopoulou</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinzii</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Johnsen</surname>
                    <given-names>SD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kurth</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eggers</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palenzuela</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tanji</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonilla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Vivo</surname>
                    <given-names>DC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Navajo neurohepatopathy is caused by a mutation in the MPV17 gene.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>79</volume>
                <fpage>544</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">16909392</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.kasiviswanathan.2011.929">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kasiviswanathan</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <article-title>Biochemical analysis of the G517V POLG variant reveals wild-type like activity.</article-title>
                <source>Mitochondrion.</source>
                <year>2011</year>
                <volume>11</volume>
                <fpage>929</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">21856450</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.kaukonen.2000.782">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kaukonen</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Juselius</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kyttala</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Keranen</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltonen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Role of adenine nucleotide translocator 1 in mtDNA maintenance.</article-title>
                <source>Science.</source>
                <volume>289</volume>
                <fpage>782</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">10926541</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.kelly.2000.170">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kelly</surname>
                    <given-names>DA</given-names>
                  </name>
                </person-group>
                <year>2000</year>
                <article-title>Liver transplantation: to do or not to do?</article-title>
                <source>Pediatr Transplant.</source>
                <volume>4</volume>
                <fpage>170</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">10933314</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.kornblum.2013.214">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Kornblum</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nicholls</surname>
                    <given-names>TJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haack</surname>
                    <given-names>TB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000f6;ler</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peeva</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danhauser</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hallmann</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zsurka</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rorbach</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Iuso</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wieland</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sciacco</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ronchi</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moggio</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Quinzii</surname>
                    <given-names>CM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mootha</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Klopstock</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strom</surname>
                    <given-names>TM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meitinger</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Minczuk</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunz</surname>
                    <given-names>WS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Prokisch</surname>
                    <given-names>H</given-names>
                  </name>
                </person-group>
                <article-title>Loss-of-function mutations in MGME1 impair mtDNA replication and cause multisystemic mitochondrial disease.</article-title>
                <source>Nat Genet.</source>
                <year>2013</year>
                <volume>45</volume>
                <fpage>214</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">23313956</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.lamantea.2002.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bordoni</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bono</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Papadimitriou</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spelbrink</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Silvestri</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Casari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>GP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutations of mitochondrial DNA polymerase gammaA are a frequent cause of autosomal dominant or recessive progressive external ophthalmoplegia.</article-title>
                <source>Ann Neurol</source>
                <volume>52</volume>
                <fpage>211</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12210792</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.longley.2006.1026">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clark</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yu Wai Man</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hudson</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Durham</surname>
                    <given-names>SE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nightingale</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Mutant POLG2 disrupts DNA polymerase subunits and causes progressive external ophthalmoplegia.</article-title>
                <source>Am J Hum Genet</source>
                <volume>78</volume>
                <fpage>1026</fpage>
                <lpage>34</lpage>
                <pub-id pub-id-type="pmid">16685652</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.luoma.2004.875">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luoma</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Melberg</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rinne</surname>
                    <given-names>JO</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaukonen</surname>
                    <given-names>JA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nupponen</surname>
                    <given-names>NN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chalmers</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oldfors</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rautakorpi</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Peltonen</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Majamaa</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study.</article-title>
                <source>Lancet.</source>
                <volume>364</volume>
                <fpage>875</fpage>
                <lpage>82</lpage>
                <pub-id pub-id-type="pmid">15351195</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.luoma.2007.1152">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luoma</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eerola</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ahola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hakonen</surname>
                    <given-names>AH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hellstrom</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kivisto</surname>
                    <given-names>KT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tienari</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mitochondrial DNA polymerase gamma variants in idiopathic sporadic Parkinson disease.</article-title>
                <source>Neurology.</source>
                <volume>69</volume>
                <fpage>1152</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">17846414</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.luoma.2005.1907">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Luoma</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luo</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Loscher</surname>
                    <given-names>WN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Farr</surname>
                    <given-names>CL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanschitz</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kiechl</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaguni</surname>
                    <given-names>LS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Functional defects due to spacer-region mutations of human mitochondrial DNA polymerase in a family with an ataxia-myopathy syndrome.</article-title>
                <source>Hum Mol Genet.</source>
                <volume>14</volume>
                <fpage>1907</fpage>
                <lpage>20</lpage>
                <pub-id pub-id-type="pmid">15917273</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.mancuso.2004.1777">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mancuso</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Filosto</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Oh</surname>
                    <given-names>SJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>A novel polymerase gamma mutation in a family with ophthalmoplegia, neuropathy, and Parkinsonism.</article-title>
                <source>Arch Neurol</source>
                <volume>61</volume>
                <fpage>1777</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">15534189</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.mandel.2001.337">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Szargel</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Labay</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shalata</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anbinder</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Berkowitz</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hartman</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barak</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>The deoxyguanosine kinase gene is mutated in individuals with depleted hepatocerebral mitochondrial DNA.</article-title>
                <source>Nat Genet.</source>
                <volume>29</volume>
                <fpage>337</fpage>
                <lpage>41</lpage>
                <pub-id pub-id-type="pmid">11687800</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.naess.2012.67">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naess</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barbaro</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruhn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wibom</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nennesmo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von D&#x000f6;beln</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>N-G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nemeth</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lesko</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2012</year>
                <article-title>Complete deletion of a POLG1 allele in a patient with Alpers syndrome.</article-title>
                <source>JIMD Rep.</source>
                <volume>4</volume>
                <fpage>67</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">23430898</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.naess.2009.484">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naess</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Freyer</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bruhn</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wibom</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Malm</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nennesmo</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>von D&#x000f6;beln</surname>
                    <given-names>U</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>N</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>MtDNA mutations are a common cause of severe disease phenotypes in children with Leigh syndrome.</article-title>
                <source>Biochimica et Biophysica Acta.</source>
                <volume>1787</volume>
                <fpage>484</fpage>
                <lpage>90</lpage>
                <pub-id pub-id-type="pmid">19103152</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.naviaux.2004.706">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>POLG mutations associated with Alpers' syndrome and mitochondrial DNA depletion.</article-title>
                <source>Ann Neurol</source>
                <volume>55</volume>
                <fpage>706</fpage>
                <lpage>12</lpage>
                <pub-id pub-id-type="pmid">15122711</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.naviaux.2005.491">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>KV</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>POLG mutations associated with Alpers&#x02019; syndrome and mitochondrial DNA depletion.</article-title>
                <source>Ann Neurol</source>
                <volume>58</volume>
                <fpage>491</fpage>
                <pub-id pub-id-type="pmid">16130100</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.naviaux.1999.54">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nyhan</surname>
                    <given-names>WL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Barshop</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Karpinski</surname>
                    <given-names>NC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>RH</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Mitochondrial DNA polymerase gamma deficiency and mtDNA depletion in a child with Alpers syndrome.</article-title>
                <source>Ann Neurol</source>
                <volume>45</volume>
                <fpage>54</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9894877</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.nguyen.2005.1493">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>&#x000d8;stergaard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ravn</surname>
                    <given-names>SH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Balslev</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Danielsen</surname>
                    <given-names>ER</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vardag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>McKiernan</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gray</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>POLG mutations in Alpers syndrome.</article-title>
                <source>Neurology</source>
                <volume>65</volume>
                <fpage>1493</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16177225</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.nguyen.2006.108">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>KV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sharief</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>SS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Molecular diagnosis of Alpers syndrome.</article-title>
                <source>J Hepatol.</source>
                <volume>45</volume>
                <fpage>108</fpage>
                <lpage>16</lpage>
                <pub-id pub-id-type="pmid">16545482</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.nishino.1999.689">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Nishino</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Spinassola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hirano</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1999</year>
                <article-title>Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder</article-title>
                <source>Science</source>
                <volume>283</volume>
                <fpage>689</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">9924029</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.ostergaard.2007.383">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kristensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mogensen</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duno</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shoubridge</surname>
                    <given-names>EA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wibrand</surname>
                    <given-names>F</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Deficiency of the alpha subunit of succinate-coenzyme A ligase causes fatal infantile lactic acidosis with mitochondrial DNA depletion.</article-title>
                <source>Am J Hum Genet.</source>
                <volume>81</volume>
                <fpage>383</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">17668387</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.ostergaard.2010.201">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ostergaard</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schwartz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Batbayli</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Christensen</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hjalmarson</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kollberg</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Holme</surname>
                    <given-names>E</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>A novel missense mutation in SUCLG1 associated with mitochondrial DNA depletion, encephalomyopathic form, with methylmalonic aciduria.</article-title>
                <source>Eur J Pediatr.</source>
                <volume>169</volume>
                <fpage>201</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">19526370</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.palmieri.2005.3079">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Palmieri</surname>
                    <given-names>L.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Alberio</surname>
                    <given-names>S.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pisano</surname>
                    <given-names>I.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lodi</surname>
                    <given-names>T.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Meznaric-Petrusa</surname>
                    <given-names>M.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zidar</surname>
                    <given-names>J.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>A.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Scarcia</surname>
                    <given-names>P.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontanesi</surname>
                    <given-names>F.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lamantea</surname>
                    <given-names>E.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I.</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M.</given-names>
                  </name>
                </person-group>
                <article-title>Complete loss-of-function of the heart/muscle-specific adenine nucleotide translocator is associated with mitochondrial myopathy and cardiomyopathy.</article-title>
                <source>Hum Mol Genet.</source>
                <year>2005</year>
                <volume>14</volume>
                <fpage>3079</fpage>
                <lpage>88</lpage>
                <pub-id pub-id-type="pmid">16155110</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.pagnamenta.2006.2467">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Pagnamenta</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taanman</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wilson</surname>
                    <given-names>CJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anderson</surname>
                    <given-names>NE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marotta</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Duncan</surname>
                    <given-names>AJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Laskowski</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Thorburn</surname>
                    <given-names>DR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>Dominant inheritance of premature ovarian failure associated with mutant mitochondrial DNA polymerase gamma.</article-title>
                <source>Hum Reprod.</source>
                <volume>21</volume>
                <fpage>2467</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">16595552</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.parikh.2009.414">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Parikh</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saneto</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Falk</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Anslem</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Haas</surname>
                    <given-names>R</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>A modern approach to the treament of mitochondrial diseases.</article-title>
                <source>Current Treatment Options in Neurology</source>
                <volume>11</volume>
                <fpage>414</fpage>
                <lpage>30</lpage>
                <pub-id pub-id-type="pmid">19891905</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.ponamarev.2002.15225">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ponamarev</surname>
                    <given-names>MV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nguyen</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kunkel</surname>
                    <given-names>TA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Active site mutation in DNA polymerase &#x003b3; associated with progressive external ophthalmoplegia causes Error-prone DNA synthesis.</article-title>
                <source>J Biol Chem.</source>
                <volume>277</volume>
                <fpage>15225</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">11897778</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.ricci.1992.141">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Ricci</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moraes</surname>
                    <given-names>CT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Servidei</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tonali</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bonilla</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                </person-group>
                <year>1992</year>
                <article-title>Disorders associated with depletion of mitochondrial DNA.</article-title>
                <source>Brain Pathol</source>
                <volume>2</volume>
                <fpage>141</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">1341955</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.rodriguez.2007.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rodriguez</surname>
                    <given-names>MC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>MacDonald</surname>
                    <given-names>JR</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mahoney</surname>
                    <given-names>DJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parise</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beal</surname>
                    <given-names>MF</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tarnopolsky</surname>
                    <given-names>MA</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Beneficial effects of creatine, CoQ10, and lipoic acid in mitochondrial disorders.</article-title>
                <source>Muscle Nerve.</source>
                <volume>35</volume>
                <fpage>235</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">17080429</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.rosenberg.2002.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Rosenberg</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Agarwala</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bouffard</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Davis</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fiermonte</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hilliard</surname>
                    <given-names>MS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koch</surname>
                    <given-names>T</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kalikin</surname>
                    <given-names>LM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Makalowska</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morton</surname>
                    <given-names>DH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Petty</surname>
                    <given-names>EM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weber</surname>
                    <given-names>JL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Palmieri</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kelley</surname>
                    <given-names>RI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sch&#x000e4;ffer</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Biesecker</surname>
                    <given-names>LG</given-names>
                  </name>
                </person-group>
                <year>2002</year>
                <article-title>Mutant deoxynucleotide carrier is associated with congenital microcephaly.</article-title>
                <source>Nat Genet.</source>
                <volume>32</volume>
                <fpage>175</fpage>
                <lpage>9</lpage>
                <pub-id pub-id-type="pmid">12185364</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.saada.2001.342">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saada</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Shaag</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mandel</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nevo</surname>
                    <given-names>Y</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Eriksson</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Elpeleg</surname>
                    <given-names>O</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutant mitochondrial thymidine kinase in mitochondrial DNA depletion myopathy.</article-title>
                <source>Nat Genet.</source>
                <volume>29</volume>
                <fpage>342</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">11687801</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.saneto.2010.140">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saneto</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lee</surname>
                    <given-names>I-C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Koenig</surname>
                    <given-names>MK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bao</surname>
                    <given-names>X</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weng</surname>
                    <given-names>SW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>L-J</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>POLG DNA testing as an emerging standard of care before instituting valproic acid therapy for pediatric seizure disorders.</article-title>
                <source>Seizure</source>
                <volume>19</volume>
                <fpage>140</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">20138553</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.sarzi.2007.531">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Sarzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bourdon</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chr&#x000e9;tien</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zarhrate</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Corcos</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Slama</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cormier-Daire</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>de Lonlay</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Munnich</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                </person-group>
                <year>2007</year>
                <article-title>Mitochondrial DNA depletion is a prevalent cause of multiple respiratory chain deficiency in childhood.</article-title>
                <source>J Pediatr.</source>
                <volume>150</volume>
                <fpage>531</fpage>
                <lpage>4</lpage>
                <pub-id pub-id-type="pmid">17452231</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.smith.1996.235">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Smith</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mah</surname>
                    <given-names>JK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Castillo</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>1996</year>
                <article-title>Brain MR imaging findings in two patients with Alpers' syndrome.</article-title>
                <source>Clin Imaging</source>
                <volume>20</volume>
                <fpage>235</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">8959359</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.spelbrink.2001.223">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spelbrink</surname>
                    <given-names>JN</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Li</surname>
                    <given-names>FY</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Nikali</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Yuan</surname>
                    <given-names>QP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tariq</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wanrooij</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Garrido</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Comi</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morandi</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Santoro</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Toscano</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fabrizi</surname>
                    <given-names>GM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Somer</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Croxen</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Beeson</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Poulton</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Jacobs</surname>
                    <given-names>HT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Larsson</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Human mitochondrial DNA deletions associated with mutations in the gene encoding Twinkle, a phage T7 gene 4-like protein localized in mitochondria.</article-title>
                <source>Nat Genet.</source>
                <volume>28</volume>
                <fpage>223</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">11431692</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.stumpf.2011.219">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stumpf</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial DNA replication and disease: insights from DNA polymerase &#x003b3; mutations.</article-title>
                <source>Cell Mol Life Sci.</source>
                <year>2011</year>
                <volume>68</volume>
                <fpage>219</fpage>
                <lpage>33</lpage>
                <pub-id pub-id-type="pmid">20927567</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.spinazzola.2006.570">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Viscomi</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fernandez-Vizarra</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Carrara</surname>
                    <given-names>F</given-names>
                  </name>
                  <name name-style="western">
                    <surname>D'Adamo</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Calvo</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Marsano</surname>
                    <given-names>RM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Donnini</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Weiher</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Strisciuglio</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Parini</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Sarzi</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chan</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>DiMauro</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>R&#x000f6;tig</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gasparini</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Mootha</surname>
                    <given-names>VK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tiranti</surname>
                    <given-names>V</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>MPV17 encodes an inner mitochondrial membrane protein and is mutated in infantile hepatic mitochondrial DNA depletion.</article-title>
                <source>Nat Genet.</source>
                <volume>38</volume>
                <fpage>570</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">16582910</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.stewart.2010.1791">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Stewart</surname>
                    <given-names>JD</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Horvath</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Baruffini</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrero</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bulst</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Watkins</surname>
                    <given-names>PB</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Fontana</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Day</surname>
                    <given-names>CP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Chinnery</surname>
                    <given-names>PF</given-names>
                  </name>
                </person-group>
                <article-title>Polymerase &#x003b3; gene POLG determines the risk of sodium valproate-induced liver toxicity.</article-title>
                <source>Hepatology</source>
                <year>2010</year>
                <volume>52</volume>
                <fpage>1791</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">21038416</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.taanman.2009.248">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Taanman</surname>
                    <given-names>JW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rahman</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Pagnamenta</surname>
                    <given-names>AT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Morris</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bitner-Glindzicz</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>NI</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leonard</surname>
                    <given-names>JV</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Clayton</surname>
                    <given-names>PT</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schapira</surname>
                    <given-names>AH</given-names>
                  </name>
                </person-group>
                <year>2009</year>
                <article-title>Analysis of mutant DNA polymerase gamma in patients with mitochondrial DNA depletion.</article-title>
                <source>Hum Mutat.</source>
                <volume>30</volume>
                <fpage>248</fpage>
                <lpage>54</lpage>
                <pub-id pub-id-type="pmid">18828154</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.tang.2012.862">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dimberg</surname>
                    <given-names>EL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <article-title>Mitochondrial neurogastrointestinal encephalomyopathy (MNGIE)-like phenotype: an expanded clinical spectrum of POLG1 mutations.</article-title>
                <source>J Neurol.</source>
                <year>2012</year>
                <volume>259</volume>
                <fpage>862</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">21993618</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.tzoulis.2006.1685">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tzoulis</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelsen</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Telstad</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aasly</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winterthun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Aarseth</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindoff</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2006</year>
                <article-title>The spectrum of clinical disease caused by the A467T and W748S POLG mutations: a study of 26 cases.</article-title>
                <source>Brain.</source>
                <volume>129</volume>
                <fpage>1685</fpage>
                <lpage>92</lpage>
                <pub-id pub-id-type="pmid">16638794</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.van_goethem.2001.211">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Goethem</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dermaut</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Lofgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2001</year>
                <article-title>Mutation of POLG is associated with progressive external ophthalmoplegia characterized by mtDNA deletions.</article-title>
                <source>Nat Genet.</source>
                <volume>28</volume>
                <fpage>211</fpage>
                <lpage>2</lpage>
                <pub-id pub-id-type="pmid">11431686</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.van_goethem.2003a.175">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Goethem</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;fgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dermaut</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceuterick</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003a</year>
                <article-title>Digenic progressive external ophthalmoplegia in a sporadic patient: recessive mutations in POLG and C10orf2/Twinkle.</article-title>
                <source>Hum Mutat.</source>
                <volume>22</volume>
                <fpage>175</fpage>
                <lpage>6</lpage>
                <pub-id pub-id-type="pmid">12872260</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.van_goethem.2004.1251">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Goethem</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Luoma</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Rantam&#x000e4;ki</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Al Memar</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kaakkola</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Hackman</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Krahe</surname>
                    <given-names>R</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;fgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Suomalainen</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Udd</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2004</year>
                <article-title>POLG mutations in neurodegenerative disorders with ataxia but no muscle involvement.</article-title>
                <source>Neurology.</source>
                <volume>63</volume>
                <fpage>1251</fpage>
                <lpage>7</lpage>
                <pub-id pub-id-type="pmid">15477547</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.van_goethem.2003b.133">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Van Goethem</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Martin</surname>
                    <given-names>JJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dermaut</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>L&#x000f6;fgren</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wibail</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ververken</surname>
                    <given-names>D</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Tack</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Dehaene</surname>
                    <given-names>I</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Zandijcke</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moonen</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ceuterick</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>De Jonghe</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Van Broeckhoven</surname>
                    <given-names>C</given-names>
                  </name>
                </person-group>
                <year>2003b</year>
                <article-title>Recessive POLG mutations presenting with sensory and ataxic neuropathy in compound heterozygote patients with progressive external ophthalmoplegia.</article-title>
                <source>Neuromuscul Disord.</source>
                <volume>13</volume>
                <fpage>133</fpage>
                <lpage>42</lpage>
                <pub-id pub-id-type="pmid">12565911</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.visser.2011.218">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Visser</surname>
                    <given-names>NA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Braun</surname>
                    <given-names>KP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Leijten</surname>
                    <given-names>FS</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van Nieuwenhuizen</surname>
                    <given-names>O</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wokke</surname>
                    <given-names>JH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>van den Bergh</surname>
                    <given-names>WM</given-names>
                  </name>
                </person-group>
                <article-title>Magnesium treatment for patients with refractory status epilepticus due to POLG1-mutations.</article-title>
                <source>J Neurol.</source>
                <year>2011</year>
                <volume>258</volume>
                <fpage>218</fpage>
                <lpage>22</lpage>
                <pub-id pub-id-type="pmid">20803213</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.winterthun.2005.1204">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Winterthun</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ferrari</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>He</surname>
                    <given-names>L</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Taylor</surname>
                    <given-names>RW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Turnbull</surname>
                    <given-names>DM</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Engelsen</surname>
                    <given-names>BA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Moen</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bindoff</surname>
                    <given-names>LA</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Autosomal recessive mitochondrial ataxic syndrome due to mitochondrial polymerase gamma mutations.</article-title>
                <source>Neurology.</source>
                <volume>64</volume>
                <fpage>1204</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15824347</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.wolf.2005.441">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wolf</surname>
                    <given-names>B</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Biotinidase: its role in biotinidase deficiency and biotin metabolism.</article-title>
                <source>J Nutr Biochem</source>
                <volume>16</volume>
                <fpage>441</fpage>
                <lpage>5</lpage>
                <pub-id pub-id-type="pmid">15992688</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.wong.2008.e150">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Brunetti-Pierri</surname>
                    <given-names>N</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>Q</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>ES</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Truong</surname>
                    <given-names>C</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Milone</surname>
                    <given-names>M</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wical</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Ganesh</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Basinger</surname>
                    <given-names>AA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Burton</surname>
                    <given-names>BK</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Swoboda</surname>
                    <given-names>K</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Gilbert</surname>
                    <given-names>DL</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Vanderver</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Saneto</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Maranda</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Arnold</surname>
                    <given-names>G</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Abdenur</surname>
                    <given-names>JE</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Waters</surname>
                    <given-names>PJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2008</year>
                <article-title>Molecular and clinical genetics of mitochondrial diseases due to POLG mutations.</article-title>
                <source>Hum Mutat.</source>
                <volume>29</volume>
                <fpage>E150</fpage>
                <lpage>E172</lpage>
                <pub-id pub-id-type="pmid">18546365</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.w_rle.1998.63">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>W&#x000f6;rle</surname>
                    <given-names>H</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Kohler</surname>
                    <given-names>B</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schlote</surname>
                    <given-names>W</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Winkler</surname>
                    <given-names>P</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bastanier</surname>
                    <given-names>CK</given-names>
                  </name>
                </person-group>
                <year>1998</year>
                <article-title>Progressive cerebral degeneration of childhood with liver disease (Alpers-Huttenlocher disease) with cytochrome oxidase deficiency presenting with epilepsia partialis continua as the first clinical manifestation.</article-title>
                <source>Clin Neuropathol</source>
                <volume>17</volume>
                <fpage>63</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">9561326</pub-id>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
        <sec id="alpers.Suggested_Reading">
          <title>Suggested Reading</title>
          <ref-list id="alpers.Suggested_Reading.reflist0">
            <ref id="alpers.REF.alpers.1931.469">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Alpers</surname>
                    <given-names>BJ</given-names>
                  </name>
                </person-group>
                <article-title>Diffuse progressive degeneration of the gray matter of the cerebrum.</article-title>
                <source>Arch Neurol Psychiatry</source>
                <year>1931</year>
                <volume>25</volume>
                <fpage>469</fpage>
                <lpage>505</lpage>
              </element-citation>
            </ref>
            <ref id="alpers.REF.cohen.2010.364">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <year>2010</year>
                <article-title>The clinical diagnosis of POLG disease and other mitochondrial DNA depletion disorders.</article-title>
                <source>Methods.</source>
                <volume>51</volume>
                <fpage>364</fpage>
                <lpage>73</lpage>
                <pub-id pub-id-type="pmid">20558295</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.copeland.2012.64">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <article-title>Defects in mitochondrial DNA replication and human disease.</article-title>
                <source>Crit Rev Biochem Mol Biol.</source>
                <year>2012</year>
                <volume>47</volume>
                <fpage>64</fpage>
                <lpage>74</lpage>
                <pub-id pub-id-type="pmid">22176657</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.longley.2005.125">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Longley</surname>
                    <given-names>MJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Graziewicz</surname>
                    <given-names>MA</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Bienstock</surname>
                    <given-names>RJ</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Consequences of mutations in human DNA polymerase gamma.</article-title>
                <source>Gene.</source>
                <volume>354</volume>
                <fpage>125</fpage>
                <lpage>31</lpage>
                <pub-id pub-id-type="pmid">15913923</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.saneto.2013.167">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Saneto</surname>
                    <given-names>RP</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Cohen</surname>
                    <given-names>BH</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Copeland</surname>
                    <given-names>WC</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Naviaux</surname>
                    <given-names>RK</given-names>
                  </name>
                </person-group>
                <article-title>Alpers-Huttenlocher syndrome.</article-title>
                <source>Pediatr Neurol.</source>
                <year>2013</year>
                <volume>48</volume>
                <fpage>167</fpage>
                <lpage>78</lpage>
                <pub-id pub-id-type="pmid">23419467</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.spinazzola.2005.162">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Spinazzola</surname>
                    <given-names>A</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zeviani</surname>
                    <given-names>M</given-names>
                  </name>
                </person-group>
                <year>2005</year>
                <article-title>Disorders of nuclear-mitochondrial intergenomic signaling.</article-title>
                <source>Gene.</source>
                <volume>354</volume>
                <fpage>162</fpage>
                <lpage>8</lpage>
                <pub-id pub-id-type="pmid">15921863</pub-id>
              </element-citation>
            </ref>
            <ref id="alpers.REF.tang.2011.s166">
              <element-citation publication-type="journal">
                <person-group>
                  <name name-style="western">
                    <surname>Tang</surname>
                    <given-names>S</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Schmitt</surname>
                    <given-names>E</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Zhang</surname>
                    <given-names>VW</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wang</surname>
                    <given-names>J</given-names>
                  </name>
                  <name name-style="western">
                    <surname>Wong</surname>
                    <given-names>LJ</given-names>
                  </name>
                </person-group>
                <year>2011</year>
                <article-title>An ever expanding molecular and clinical spectrum of polg revealed by the study of a large patient cohort.</article-title>
                <source>J Inherit Metab Dis.</source>
                <volume>34</volume>
                <supplement>Suppl 3</supplement>
                <fpage>S166</fpage>
              </element-citation>
            </ref>
          </ref-list>
        </sec>
      </sec>
      <sec id="alpers.Chapter_Notes">
        <title>Chapter Notes</title>
        <sec id="alpers.Revision_History">
          <title>Revision History</title>
          <list list-type="bullet">
            <list-item>
              <p>18 December 2014 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>11 October 2012 (me) Comprehensive update posted live</p>
            </list-item>
            <list-item>
              <p>16 March 2010 (me) Review posted live</p>
            </list-item>
            <list-item>
              <p>9 December 2007 (bhc) Original submission</p>
            </list-item>
          </list>
        </sec>
      </sec>
    </body>
  </book-part>
</book-part-wrapper>
